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Abstract

Receptor for hyaluronan mediated motility (Rhamm), is a extracellular receptor for
hyaluronan, which is over-expressed in breast cancer. To develop imaging probes for
Rhamm, peptide mimics of hyaluronan (HA) were developed using: (1) screening of
combinatorial peptide library, and (2) basic local alignment search tool (BLAST) to
elucidate proteins high affinity ligands. Using combinatorial approach, a library
consisting of D-peptides was screened and resulted in 15 novel peptides showing
micromolar affinities. Through rational-based approach, 17 tubulin-derived peptides
were screening using surface plasmon spectroscopy (SPR) and resulted in 6 high affinity
ligands with nanomolar affinities. Using enzyme-linked immunosorbent assay (ELISA),
candidate peptides from the two approaches showed specificity to the Rhamm's HA
binding domain and were able to compete with HA for binding.
Rhenium (I) complexes containing the/oc-M(CO)3+ moieties served as surrogates for fac99mTc(CO)3+ complexes, which are fundamental in the development of radioactive
products for diagnostic applications. Rhenium tricarbonyl complexes incorporating biand tridentate bis(l-methylbenzimidazol-2-yl) ligands were developed, synthesized and
characterized spectroscopically.
Keywords: Receptor for hyaluronan mediated motility, tubulin carboxy terminal tails,
hyaluronan, cancer, molecular imaging, probe design, technetium rhenium tricarbonyl,
bis-benzimidazole, benzimidazole.
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1.

Introduction

1.1.

Molecular Imaging

Molecular imaging is defined as a discipline aimed at visualization, characterization and
measurement of biological processes noninvasively at the molecular and cellular levels
in biological systems. Central to this discipline is the development of molecular imaging
probes which are used to elucidate and quantify biological processes such as metabolic
activity, cell proliferation, apoptosis, receptor occupancy, reporter gene expression,
and/or disease progression. Molecular imaging probes are designed to target a
particular site within the body and their concentration and/or spectral properties are
altered by the specific biological process under investigation. Typically, disease states
such as cancer accompany changes in receptor concentration, thus the use of a
receptor-specific ligand as a targeting moiety creates a target-directed molecular
imaging probe capable of selective imaging of a particular site within the body.

/
T a r g e t in g E n t it y

L in k e r

A

\

Figure 1: Components of a molecular imaging probe. The label provides a signal to be detected and denotes the type
of imaging modality used. The linker distances the targeting entity from the label to allow proper receptor-ligand
binding. The use of a spacer has been shown to reduce the steric hindrance that can occur when the targeting entity
conjugates to its biological receptor. The targeting entity gives the probe specificity due to its high affinity to a
particular biological receptor.

A molecular imaging probe (Figure 1) consists of two main components: (1) the
"targeting entity", that is a chemical entity (e.g. small molecule, peptide, protein or
1

other bio-molecule) specifically tailored to recognize and bind with high affinity to a
particular biological receptor and (2) the "label" whose function is to provide a signal for
detection. The label can be a light- or near-infrared emitting molecule (e.g. a dye) or a
radioisotope. A radioisotope is a molecule, possessing a relatively short half-life, which
releases radiation of appropriate energy high enough for detection and low enough to
avoid exposure to harmful ionizing radiation. Dyes (or fluorophores), another type of
label, are molecules which fluoresce upon the absorption of light at a specific
wavelength.

A

B

Figure 2: Examples of molecular imaging probes. (A) Structure of c(RGDyK) conjugated to Cy5.5 near-infrared dye. (B)
Structure of octreotide labelled with 18F radionuclide, a common isotope for nuclear imaging. Molecular imaging
probe labels are boxed in teal.

To date, a large variety of sophisticated imaging probes have been developed by
combining various labels and targeting entities.1 For instance, polypeptide domains
containing the R-G-D peptide sequence has been shown to bind to a vp3 receptor, an
integrin receptor known to be over expressed on proliferating endothelial cells during
angiogenesis and metastasis.2,3 Cyclic-RGD peptides conjugated to Cy5.5 dye (a type of
near-infrared dye) has been shown to image integrin-positive tumours in vivo (Figure
2

2A).4 Also, octreotide imaging probes (Figure 2B) have been reported to target
neuroendocrine tumours and somatostatin receptor positive cancer cells. 5,6

1.2.

Fluorescence and SPECT Imaging

Different imaging modalities are used to monitor molecular imaging probes in biological
systems, and typically the label denotes the type of imaging modality used. For instance,
probes which are conjugated to a dye generally use fluorescence imaging and probes
that utilize radioisotopes uses nuclear imaging such as single photon emission computed
tomography (SPECT).
In SPECT imaging, photons are detected using a gamma detector which rotates around
the subject under investigation forming a three dimensional image. Within the detectors
are parallel slits which filters rays, thus collecting only collimated gamma rays and
excludes any radiation outside of the area of focus. Collimated rays are detected within
the slits and are converted to digital signal for display.

Another type of imaging modality, called fluorescence imaging, uses fluorophores
instead of radionuclides. Dyes are commercially available and come with a variety of
activated groups (e.g. NHS-ester activated carboxylates) which are easily incorporated
to a compatible prosthetic functional group (e.g. amines for this particular case) within
the targeting entity. This type of imaging utilizes a tunable light of a particular
wavelength to excite a dye, and detection of the emitted light of specific but longer
wavelength.

3

1.3.

Receptor for Hyaluronan Mediated Motility (Rhamm) and Cancer

Hyaluronan (HA), a polysaccharide consisting of dimeric repeats of D-glucuronic acid and
/V-acetylglucosamine, is a glycosaminoglycan essential for proper cell growth, organ
structural stability and tissue organization.7,8 HA affects cellular processes by interacting
with receptors on the cell surface. In many cancers of epithelial origin, there is upregulation of cell-surface HA receptors.9,10 Furthermore, many of the downstream
pathways (e.g. kinase-AKT pathways and Ras-MAPK signaling11) following the activation
of these receptors are deregulated in cancers, leading to tumor growth, progression and
metastasis.12,13,14 The receptor for hyaluronan mediated motility (Rhamm) is a
extracellular HA binding protein that regulates cell proliferation and promotes cell
locomotion.15,16 Rhamm is over-expressed in metastatic cancers (e.g. prostate and
breast), and in both acute and chronic leukemia.17,18,19,20 Rhamm has been implicated in
tumour metastasis, in particular, the processes of cell motility and invasion.21,22,23 Thus,
Rhamm could potentially be used as a molecular target for cancer diagnosis.
The HA-binding motif of Rhamm has been identified near the carboxy-terminus, and
consists of two basic amino acids flanking a seven amino acid stretch, B(X)7B, in which B
is either Lys or Arg and the X7 contains no acidic residues.24,25 Synthetic peptides
representing this domain inhibit HA binding to full length Rhamm, while peptides
representing other parts of the primary sequence fail to inhibit binding.26 The
interaction of HA with Rhamm is believed to be based on ionic contacts between
positively charged residues in the protein and negatively charged carboxylate groups on
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HA, as well as potential hydrophobic interactions involving lipophilic patches on
Rhamm.27

1.4.

Design of Hyaluronan Mimetic Peptides

Proteins which interact with carbohydrates are attractive drug/imaging probe targets in
that they are involved in many biological processes.

Protein-sugar interactions can be

inhibited by the administration of structurally related carbohydrates, but this approach
is strongly hampered by the lack of robust methods for the synthesis of carbohydrates.29
An alternative method is to use a non-carbohydrate-based scaffold to project the
essential functionality that would enable structural resemblance to a particular type of
carbohydrate.27
Recently, peptides have attracted increasing attention for their use in the design of
drugs/targeting agents due to several advantages: (1) peptides show higher specificity
for their target at nanomolar concentrations30; (2) low toxicity in animal systems; (3)
peptides can be easily synthesized and modified structurally to improve their stability
against proteolytic degradation, thus increasing half-life in biological systems30; and (4)
compared to macromolecular targeting agents, peptides are low in molecular weight
causing them to have higher tissue and cell permeability.30

5

Figure 3: Chemical structure of hyaluronan (bottom) and a putative hyaluronan peptide mimic (top), indicating the
carboxylates required for binding to Rhamm.

Carbohydrates display remarkable biological activities, but problems associated with
synthesis, degradation and delivery hinders their potential to be used as molecular
imaging probes.31 Thus, identifying peptides that selectively bind to carbohydrate
receptors using classical approaches of drug/probe design, could aid in development of
chemical entities targeting protein-carbohydrate mediated disease states. In this study,
peptides with the same structural features to that of HA, a type of carbohydrate, are
created in order to mimic its physio-chemical properties towards Rhamm. For instance,
it can be postulated that acidic residues, with the appropriate configurations,
strategically placed within a peptide backbone could potentially mimic the carboxylates
of HA (Figure 3).
The process of obtaining new targeting entities consists of several steps and may
require different technologies for biological characterization (Scheme 1). Typically,
designing targeting entities for molecular imaging probes requires a well characterized
6

protein target and a method for ligand identification. Classically, probe development
involves attaching a label to a selected endogenous ligand, followed by studies which
characterize the distribution and specificity of the probe.32 However, this type of
development is time consuming and requires a well-characterized protein-ligand
interaction. Another type of probe development involves screening or testing specificity
of large number of ligands to a particular biological receptor. This form of probe
development involves fixed criteria in screening, followed by the screening itself, and
then further validation to address potential issues associated with the screening.

In Vitro
Target
Validation
Potential ligands

Validation
• Candidate
Compounds

Validated "Hit"
compounds

Screening

Scheme 1: Initial stages of Imaging probe development.

Despite improvement in the selection of imaging probes, false positives can still arise;
and for this reason, those potential compounds identified by the initial screening needs
to be confirmed and validated using in vitro assays before being considered as "hits".
Finally after intensive probe characterization, one or several "hit" compounds showing
activity over a certain threshold are obtained.
7

In designing peptides which mimics the binding of HA, two approaches were
undertaken: (1) rational-based design which uses ligand-based and structural-based
approaches; and (2) a method utilizing screening of a random combinatorial peptide
library. The resulting "hits" from the different method were further characterized using
in vitro assays.

1.4.1. Rational Approach
Some rational approaches for the design of imaging probe/drug utilizes bioinformatics
to predict potential targeting entities against the desired protein.33'34 Bioinformatics is a
discipline which involves the use of techniques including applied mathematics,
informatics, computer science, chemistry, biochemistry and computational techniques.
This approach necessitates the availability of previous information regarding the target
protein structure and/or primary sequence. Implored rational approaches to imaging
probe design for targeting Rhamm consisted of two types of experimental methods: (1)
structure-based design and (2) ligand-based design.

1.4.1.1. Structure-Based Design
Most structure-based approaches are based on docking calculations, which enables
visual inspection of the results leading to a better understanding of the ligand-protein
binding process.

o r

Recent advances in methods for protein expression and production,

computational biochemistry, NMR spectroscopy and X-ray crystallography have led to a
significant rise in the number of protein structures solved.36 Many of these structures
are deposited and made publicly accessible in online databases such as Protein Data
8

Bank (PDB), and currently containing over 47,000 entries and its size is continually
increasing annually.37 Accordingly, using PDB data, it is now possible to generate models
from protein cavities to profile similarities against multiple proteins,38 and dock a single
molecule against a many binding sites extracted from the PDB.39
However, despite the great number of data within the PDB, the application of structurebased methods in the design of targeting entities for molecular imaging is often limited
by the relatively low experimentally-determined structures since most entries are
unevenly distributed among the protein members of the main target families of interest.
For instance, while enzymes (37%) and nuclear receptors (51%) constitutes most of PDB,
membrane spanning receptors (trans-membrane proteins) and recently discovered
proteins are almost devoid of structural information.40
Aside from having access to prior knowledge, designing imaging probes to a particular
protein family requires a method of elucidating compounds with the right moiety which
are complementary to the protein cavity of interest.41 Computed-aided drug/probe
design is a research discipline centered on bioinformatics which includes development
of digital repositories for the study of chemical relationships, computer programs for
designing compounds with interesting physiochemical characteristics, and tools for the
systematic assessment of potential compounds.42 Protein threading or side chain
conformation search is a computational method for designing drugs/probes which
allows for backbone modelling of a source structure and permits the modelled structure
to be compared to structurally conserved proteins with reported crystal structure within
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a database.43,44'45 This could provide the foundation for probe design by providing data
which can be modelled in 3D by modeling programs (such as SWISS-MODEL46,
COMPOSER47, 3D-JIGSAW48, SegMod/ENCAD49). Finally, ligands are placed within the
active site and then modified to fill the space available.50,51 Also, energies of binding,
free energies of perturbation and other thermodynamic parameters could be performed
using software tools such as DOCK.52
A peptide, containing the sequence YDSeYeSe, (NB lower case letters denote amino
acids with D-configuration) which showed binding affinity to Rhamm was previously
identified by Prestwich using rational based design of a peptide library.53 Furthermore,
Ziebell et at. characterized the binding of this molecule by computationally docking it
onto a molecular model of Rhamm.54 In Chapter 1, this model peptide was further
developed via characterization by in vitro assays, and was conjugated to a metal to
create a surrogate probe for nuclear imaging. To this end, the optimal placement of a
metal chelator was elucidated, and a metal chelator in the form of N,Nbis(quinolinoyl)amine was incorporated to the peptide.

I.4 .I.2 . Ligand-Based Design
A ligand-based approach utilizes knowledge of the target protein structure and ligands
which could potentially bind to the protein of interest. In other words, targeting entities
could be developed using information regarding the biological target and what
surrogate molecules bind to it; and this in turn may be used as a model to design new
molecular entities that interact with the target.
10

With the advent of bioinformatics, protein function can be elucidated by matching the
desired protein's primary sequence to previously reported proteins whose function has
been established with experimental evidence. Sequence alignment tools such as BLAST55
and PSI-BLAST56 allows for protein sequences to be screened to large online databases
(e.g. COGs57, ProDom58, Pfam59, SMART60, PRINTS61) to determine proteins which show
high level of sequence similarity and allows evaluation the alignment using sequence
comparison parameters (such as substitution matrices, gap penalties, and propensity
scales).62
Using bioinformatics, functional classifications (i.e. sequence-based classification) of
many protein families that share consensus protein sequences were created and had a
profound influence on the way novel ligands are discovered. This method of
classification allowed identification of conserved binding sites within protein families,
which could then be translated into a conservation of architectures of binding sites that
enables proper binding.63 Since protein-protein contacts is mediated by interactions of
corresponding binding sites within the two interacting proteins, ligand structures based
on the primary sequence of the active site of one interacting protein could be
elucidated.64 This classification scheme implies that a particular class of compound
which is active against a particular protein can potentially be active to the entire protein
family, even though other family members have different biological function.65 In other
words, a ligand-based approach relies on the principal notion that similar conserved
protein sequences (and by extension, similar molecules) exhibit more or less similar
properties.66
11

In Chapter 2, ligand-based rational design was employed using sequence homology to a
database of known proteins with reported ligands, using the basic local alignment
search tool (BLAST) to discover peptides which show high affinity for Rhamm. Structural
homology between proteins can be seen as a function of sequence similarities, thus
proteins (and protein fragments) which bind to a characteristic sequence motif in
another protein that show high homology to the HA binding domain sequence can be
used as targeting moiety in probes designed to target Rhamm.

1.4.2. Library-Based Approach
In the past, potential ligands were identified individually using in vitro assays towards a
single purified target. Now, the advent of combinatorial chemistry and high-throughput
screening allows for rapid identification of potential ligands. Combinatorial chemistry
allows for increased capacity for synthesizing compounds while high-throughput
screening allows for rapid testing of compounds on in vitro target-based assay.

Figure 4: General schematic of solid phase synthesis. Solid supports (denoted by S) are allowed to react to large
excess of reagents (denoted by □) in the first step. Purification of compounds bound to solid support from those in
solution is accomplished by simple filtration and multiple washings.
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Combinatorial chemistry utilizes parallel synthesis of a large number of compounds in a
short amount of time on solid support (Figure 4). In this study, a combinatorial peptide
library is utilized to create a pool of peptides. This peptide library is expected to contain
a diverse set of small molecules, which have the potential to probe a selected targeted
protein. Peptide-based targeting of tumour-associated proteins is particularly attractive
in molecular imaging because high affinity sequences can easily be discovered de novo
through screening of synthetic peptide libraries. A synthetic peptide library consists of
beads each carrying a single species of covalently bound peptide.67 Peptide libraries
have two distinct advantages for ligand screening: (1) unnatural amino acids, D-amino
acids and even non-peptide moieties can be incorporated in the construction of
synthetic peptide library, (2) beads can be screened using diverse bioassays that uses
purified proteins, cells and/or crude cellular extracts.68,69

\
04
D *
S p lit

C o u p lin g o f
1st AA

M ix an d S p lit

C o u p lin g o f 2nd
AA

Figure 5: Split/Mix synthesis method for creating combinatorial peptide library. Yellow circles represent beads and
coloured circles represent amino acids.
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A random peptide library is created using split/mix synthesis method (Figure 5).70 This
synthesis method involves distribution of carrier beads (approximately 90 pm in
diameter) into separate reaction vessels each containing a single amino acid. After the
coupling of the first amino acids, the beads are re-pooled and the cycle is repeated
several times to extend the peptide chain to the desired length. Following the creation
of the library, it is screened against purified protein. To this end, beads are incubated
with purified protein and bead-protein complex is identified via high-throughput
screenings such as protein-charged magnetic bead screening assay71 or enzyme-linked
screening assay.72 After screening, peptides identity contained within each isolated bead
can be determined using methods such as automated Edman degradation,73 MALDI
deconvolution,74

chromatography

selection,75

positional

scanning

synthetic

combinatorial library.76
In Chapter 3, a combinatorial peptide library consisting of peptides arising from the
random combination of D-amino acids is utilized. The resulting library is screened
against purified Rhamm and candidate peptides were evaluated to further test their
potential as targeting agent for imaging probes specific for Rhamm.

1.5. Objectives
HA-based imaging probes (e.g. HA conjugated to radionuclides and MRI contrast agents)
targeting Rhamm have been reported.77 However, due to non-specific binding to other
extracellular surface receptors, high concentrations of HA-based probes are needed to
image tumours.78 Thus, peptides that mimic the binding properties of HA are proposed
14

as an alternative approach to HA-based probes. Furthermore, this project intends to
develop a peptide-based imaging probe that shows significant uptake into Rhammexpressing breast tumour cells while demonstrating variably low uptake in normal (nonRhamm expressing) cells.
It was envisaged that these novel peptides will lead to the generation of a class of
imaging agents with unique and superior biological properties to that of the natural
ligand HA. These advantages include: (1) these peptides can be specifically tailored to
bind to the HA binding domain of Rhamm, thus minimizing interaction to other
hyaladerins (e.g. CD44) and providing a reagent for tumour subset specificity; (2)
Tumour cells also express high levels of HA and hyaluronidase (a protein which rapidly
degrades endogenous HA),79 thus HA-based probes must not only compete with high
levels of endogenous HA but are rapidly degraded at the tumour site; (3) Since HA is a
polymer (approx. 350,000 Da), it is expected that these low molecular weight peptides
will penetrate tumours to a greater extent than HA; and finally, (4) these peptides might
not be recognized by the liver cell receptors involved in HA clearance from the
bloodstream, thus increasing its concentration in tumours. In summary, this research
aims to design, synthesize and in vitro characterize optical and metal conjugated
peptides as HA mimics.
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2. Structural Design: Design, synthesis and
characterization of metal conjugated HA mimic as a
surrogate for imaging probes for cancer.

2.1. Introduction

2.1.1. Hyaluronan-Binding Motif of Rhamm
Receptor for hyaluronan mediated motility (Rhamm) contains an HA-binding domain
localized to a 62-amino acid segment (SI) at the carboxy terminus of the protein that is
lacks structural similarities with traditional HA-binding motifs found in many HA surface
receptors.80 Circular dichroism experiments show that S I is predominantly helical, which
is comparatively different from the P-sheet dominated HA-binding region of other
hyaladerins.81 Although the crystal structure of Rhamm has not been elucidate to date,
the structure of the aforementioned 62-amino acid segment along with HA has been
elucidated in using a combination of solution phase NMR and molecular modelling.81
This structural information regarding the HA-binding domain of Rhamm can then be
used to reveal important information regarding the mechanism of HA binding and the
regulatory role ligand binding might play in conformational changes of Rhamm. For
instance, docking calculations of HA to Rhamm can provide data on the steric and
energetic restraints necessary for optimal binding, which could then be applied to
candidate ligands.
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Compound 1, previously elucidated by Ziebell et al,82 was reported to bind to the HAbinding domain of Rhamm with an affinity of 2.1 nM (Figure 6). This compound was
designed with the premise that alternating acidic residues within the peptidyl chain
places the negative charges in a similar spatial manner to that of the carboxylates on
HA.82 Furthermore, data suggests that the inclusion of D-glutamates creates a 12-14

A

distance between two neighbouring carboxylate side chains, which is close enough to
match the 10

A

separation of carboxylates on HA. However, it should be noted that

using molecular dynamics simulation, we were not able to reproduce these results.

1
Figure 6: Chemical structure of candidate targeting entity containing the peptide sequence YDSeYeSe (Note: Upper
case letters denote natural L-amino acids while lower case amino acids note unnatural D-amino acids).

As mentioned earlier, Rhamm-HA complex is mainly held by ionic interactions and thus
it is expected that high affinity ligands should also contain the same degree of
electrostatic interactions to Rhamm. HA interacts with residues Lys548, Lys553 and
Lys560, while 1 interacts with residues Lys548, Arg555, and Lys560 on Rhamm. A
common binding site in Rhamm for HA and 1 (i.e. Lys548 and Lys560) predicts potential
competition between the two ligands; for this reason, it is believed that 1 could
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potentially inhibit HA binding to Rhamm in physiological systems. Thus, compound 1 has
the potential for further probe development.

2.1.2. Rhenium and Technetium
Technetium-99m (99mTc), which has a half-life of six hours and releases gamma rays
upon decay, is one of the most widely used radionuclide due to its low cost and high
availability. In imaging, new " mTc based imaging probes use a 99mTc(CO)3+ core. This
core readily conjugates to molecules by complexing to a variety of ligand systems (such
as N-heterocycles, amines, carboxylic acid, thioesters, thiols and combinations thereof)
present in commercially available " mTc (CO)3+ chelators (Figure 7).

r-

Figure 7: Schematic of M(CO)3L complex. M
represents Re/"mTc while L represents any
tridentate ligand donors
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This core structure is particularly attractive because the low spin d6 Tc (I) center is
chemically inert and allows three facial positions for ligand substitution.

on

Rhenium (Re)

is a non-radioactive element located one row beneath technetium in the periodic table,
has two stable nuclei (185Re (37.4%) and 187Re (62.6%)) and is found to have similar size
and formal charge as technetium.84 Re complexes can serve as structural models for Tc
complexes because homologous compounds have very similar coordination parameters.
Thus, analogous Re and Tc complexes are nearly identical and are potentially
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indistinguishable in biological systems. Thus, rhenium provides a suitable method for
the structural characterization of compounds, while avoiding any radioactivity.
The Re/99mTc(CO)3+ core is relatively small and lipophilic, thus allowing it to be tightly
bound by tridentate chelators in aqueous biological settings.

or

The facial carbonyl

ligands have been known to make their trans positioned ligands to be more labile,
allowing easy incorporation in chelation sites of an imaging probes. For instance,
R e /"mTc (CO)3+ cores with halides (Cl' or Br ) defining the other face of the complex
easily dissociates in water to produce/oc-[Re(CO)3(OH2)3]+. 85 The facial arrangement of
the carbonyls also makes fewer products upon complexation as it provides a limited
variation in ligand configuration.
Compound 1 was further developed and characterized using in vitro assays, and was
conjugated to a Re(CO)3+ core to create a surrogate probe for nuclear imaging. To this
end, the optimal placement of a Re(CO)3+ chelator was elucidated, and a metal chelator
in the form of N,N-bis(quinolinoyl)amine was incorporated to the peptide.

2.2.

Results and Discussion

2.2.1. Initial Studies
To examine the potential of peptide 1 as a metal conjugated molecular imaging probe,
the affinity of the peptide to Rhamm was first examined. The peptide was synthesized
using solid phase peptide synthesis (SPPS), purified and conjugated to 0.2 pm aldehydesulphate charged fluorescent beads (FluoSpheres®) using reductive amination. The
amino group of the peptide (compound 1) was reacted with the aldehyde functionality
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of the FluoSpheres in methanol, and the resulting ¡mine was reduced using sodium
cyanoborohydride. Non-conjugated peptides were removed via dialysis in water.
FluoSpheres were chosen due to high dye equivalent per microsphere and increased
resistance to photobeaching.86 Figure 8A gives the pictograph representation of
peptide-charged FluoSpheres (ModFluoSpheres).

-H A

+ HA

+ HA

Figure 8: (A) Pictographic representation of ModFluoSpheres. (B) Blinding of ModFluoSpheres to Rhamm using ELISA.
In each assay, Rhamm bound to a 96-well plate was used as the primary protein. Fluorescent beads have maxima at
405 nm. Data are the mean of four experiments, analyzed using ANOVA, and error bars shown are the standard error
of the mean. Background (no immobilized Rhamm) signal was subtracted for each treatment groups.

To assess specificity, the ability of ModFluoSpheres to compete with HA for the HAbinding domain of Rhamm was assessed using enzyme-linked immunosorbent assay or
ELISA (Figure 8B). ELISA is a biomolecular technique used to detect the affinity of a
ligand to a specific biological receptor. Initially in an ELISA, a biomolecule is immobilized
to a plate. This step is followed by the addition of a known ligand which attaches to the
functionalized surface if it displays a binding affinity to the immobilized substrate. In this
assay, the observed fluorescence can be seen as a function of ModSpheres bound to
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immobilized Rhamm. Results indicate that ModFluoSpheres are able to compete with
HA, suggesting specificity to the HA-binding domain of Rhamm.

Previous reports on molecular docking experiments of Prestwich et al. suggest that the
amino terminus of the peptide does not seem to participate in binding. Furthermore,
experimental data suggests that functionalization (i.e. addition of FluoSpheres) at the
amino terminus of the peptide does not seem to negatively affect specificity of the
peptide to Rhamm. Therefore, it is predicted that the placement of the Re(CO)3+
chelator at the amino terminus would have negligible effect on the physio-chemical
properties of the peptide.

2.2.2. Synthesis
From initial studies, efforts were made to add a metal chelator to the peptide for
incorporation of the radioactive metal surrogate. As mentioned earlier, due to the low
cost and high availability of " mTc, it is one of the most used radionuclide in diagnostic
imaging. Since " mTc is radioactive, rhenium analogs which are non-radioactive
surrogates of technetium-99m are typically used for characterization of complexes. To
create a metal conjugated imaging probe (compound 2), a Re(CO)3+ chelator in the form
of N,N-bis(quinolinoyl)amine was utilized.87 This chelator provides a tridentate donor set
for chelation and an amine functionality for attachment to biomolecules (Figure 9). The
rhenium coordination geometry is defined by three facial carbonyl groups thus orienting
the quinolinoyl nitrogen donors and amine nitrogen to the other face.
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2
Figure 9: Proposed metal-conjugated probe for breast cancer.

Using SPPS, the amino acid corresponding to the desired sequence was added in
succession starting from the carboxy terminal of the peptide (Scheme 2). Next,
aminohexanoic acid linker was incorporated to the sequence to distance the targeting
entity to the chelator. The employed chelator was created by coupling the two
methylquinoline arms to the N-terminus of the peptide following Fmoc-deprotection. To
this end, excess 2-(chloromethyl)quinoline was reacted to the amino group of the
peptide on solid support at room temperature in DMF in the presence of a base for 24
hours. The resulting peptide was rhenium coordinated using (NEt4)2[Re(CO)3Br3] in
methanol via microwave irradiation.

^
F m o c H N -Q

1. 2 0 % P iperidin e in D M F
2. Fm oc-A m ino acids (A x), H B T U , D IP E A
______________________►
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A 2~ K ,
A fi_ A 3

F m ocH N
Scheme 2: Solid phase peptide synthesis using standard Fmoc protocols.

Prior to rhenium coordination, (NEt4)2[Re(CO)3Br3] was synthesized from reaction
between Re(CO)5Br and tetraethylammonium bromide in diglyme at 120°C for eight
hours (89% yield).88,89 Unfortunately, rhenium coordination did not proceed readily and
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resulted in poor yield (3%). Varying the amount of (NEt4)2[Re(CO)3Br3] and temperature
was performed to elucidate the optimal condition for coordination. Through evaluation
of reaction progress via HPLC, results indicate that the amount of rhenium substrate had
little or no effect on increasing product formation while temperature variations
significantly increase the amount of rhenium bound peptides (Error! Not a valid
bookmark self-reference.)Table 1: % Rhenium-bound peptides with varying temperature and amounts of (NEt4 )2[Re(CO)3Br3]. Reaction was
heated using microwave irradiation for 15 minutes. % Rhenium-bound peptides were determined using LC-MS.
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However, when the reaction done at 60°C, there was evidence of peptide degradation,
thus resulting in lower amount of product. It is also noteworthy that increasing the
duration of the reaction had little or no effect on the formation of desired product. The
resulting product was removed from solid support, purified via HPLC (89% purity) and
characterized by mass spectrometry (Figure 10).
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Figure 10: (A) HPLC trace of purified 2 with a retention time of 13.1 min displaying a purity of 89% in 12% yield. (B)
ESI-MS showing observed [M+H]+ = 1688.12 m/z (calculated 1688.74 m/z).

2.2.3. In Vitro Characterization
Rhenium tricarbonyl A^AZ-bisiquinolinoyOamine complexes have been reported to have
optical properties suitable for fluorescence imaging.

QA

Thus, the absorption and

emission maxima were determined to facilitate the further in vitro characterization of 2.
The probe was determined to have absorption maximum of 235 nm and an emission
maximum of 452 nm in methanol (Figure 11).
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Figure 11: Absorption and emission spectra of 2 in methanol. The compound shows absorption maximum of 235 nm,
and an emission maximum of 452 nm.

To determine the specificity of 2 for Rhamm expressing tumour cells, a cellular
fluorescence assay was performed. To this end, MDA-231-MB tumour cells were
incubated with 2 and emission at 452 nm, which corresponds to the emission maximum,
was recorded. Furthermore, to denote specificity to Rhamm, cells were pre-treated with
anti-Rhamm prior to incubation of 2. Figure 12 shows images and quantification of
cellular fluorescence obtained from the resulting experiments. Nuclei are labelled with
DAPI and shown in blue while probe 2 is shown in red. Data indicate that compound 2
was taken up by MDA-231-MB; however, uptake is not decreased upon treatment of
anti-Rhamm, indicating that this is non-specific uptake.
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Figure 12: Cellular uptake studies and quantification of 2 in MDA-MB-231 cancer cell line. (A) Cells incubated with the
probe. (B) Cells pre-treated with anti-Rhamm antibody and incubated with the probe. Nuclei (stained with OAPI) are
shown in blue while metal- conjugated peptides are shown in red. (C) Quantification of cellular uptake (148 ROI for
each treatment group, n = 2) showed no statistical significance between cells receiving anti-Rhamm and cells which
receive no antibody treatment.

2.3.

Conclusion

This study aims to create a metal-conjugated imaging probe as a surrogate for nuclear
imaging. The peptide, containing the sequence YDSeYeSe, which was previously
reported to have affinity to Rhamm, was examined using in vitro assays. To this end,
peptides were conjugated to fluorescent beads (FluoSpheres) and their specificity to the
HA binding domain of Rhamm was examined. Data indicate that the targeting entity was
able to compete with HA suggesting specificity to the HA binding domain of Rhamm.
Since direct conjugation of the amino terminus of the peptide to FluoSpheres does not
seem to affect specificity, the metal chelator was placed along the N-terminus spaced
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away by aminohexanoic acid linker. A/,A/-Bis(quinolinoyl)amine was incorporated to the
N-terminus of the peptide and served as a Re(CO)3+ chelator.

However, cellular fluorescence assay indicates non-specific uptake of the probe in
Rhamm-expressing tumour cells. Although, the probe shows specificity to the HA
binding region of Rhamm, as determined by ELISA, the probe might be interacting with
other surface receptors resulting in non-specific uptake. Therefore, new targeting
entities showing specificity to Rhamm expressing cells need to be discovered.

2.4.

Experimental

Solvents were used without further purification, and purchased either from VWR, Fisher
Scientific, or Sigma Aldrich. Fmoc-dGlu preload Wang resin (100-200 mesh, 0.70
mmol/g), standard Fmoc amino acids, Fmoc-aminohexanoic acid (Ahx), Fmoc-D-amino
acids, HBTU coupling reagents were obtained from Peptides International.
Chloromethylquinoline

(Sigma Aldrich), sodium cyanoborohydride

(Aldrich)

2and

Re(CO)sBr (Strem Chemicals) were purchased as reagent grade and used without further
purification. FluoSpheres aldehyde-sulfate microspheres (0.2 pm) were purchases from
Invitrogen. UV-Vis data was obtained from Beckman DU 530 spectrophotometer using
quartz cuvettes (10 mm)

2.4.1. Peptide Synthesis
Elongation of peptidyl chains on rink amide MBHA resins (0.1 mmol) was performed
using automated (APEX 396 auto-synthesizer) and manual methods using standard
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Fmoc deprotection and amino acid coupling cycles.91 Solid-phase peptide coupling
reactions were monitored using the Kaiser test.92 Repeated Fmoc deprotection
throughout the synthesis (15 and 20 minutes periods) was carried out using 20%
piperidine solution in /V,A/-dimethylformide (DMF). All amino acid couplings were carried
out using 0.05 M or higher concentration of Fmoc-protected amino acid and HBTU, 5
equivalent of /V,A/-diisopropylethylamine (DIPEA) in DMF at 30 and 90 minutes intervals.
After each deprotection and coupling step, the resin was washed repeatedly with DMF
(3x) and dichloromethane (DCM) (3x). Fmoc-protected aminohexanoic acid (Ahx) was
coupled using the same parameters.
Following the Fmoc-deprotection of Ahx linker, the peptidyl resin (0.1 mmol) was
reacted with 10-fold excess of 2-(chlorometyl)quinoline in DMF in the presence of DIPEA
(2 equiv.) at room temperature for 24 hours. Reaction completion was monitored by RPHPLC.
Purification of peptides was performed using gradient solvent system consisting of H20
+ 0.1% TFA (solvent A) and CH3CN + 0.1% TFA (solvent B) at a linear flow rate of 1.5
mL/min and 20 mL/min for analytical and preparative HPLC, respectively. Analytical
HPLC was performed using a Grace Vydac Protein/Peptide RP-C18 column (4.6 mm x 250
pm, 5 pm), and preparative HPLC was performed using a Grace Vydac protein/peptide
RP-C18 column (22.0 mm x 250 mm, 10 pm). Absorbance was detected at wavelengths
of 220 nm and 254 nm using a Waters 2998 Photodiode Array detector. During
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purification, fractions were collected, lyophilized, and analyzed by ESI-MS (Waters
Micromass Quattro Micro™ API).

2.4.2. Peptide conjugation to FluoSphere Beads
Purified peptides (10 mg, 8 equiv.) were agitated together with aldehyde-functionalized
2 pm FluoSphere beads for 2 hours in methanol (10 ml_). The resulting suspension was
treated with sodium cyanoborohydride (8 equiv.) and the reaction mixture was allowed
to stir overnight. The suspension was transferred to a dialysis tube (molecular cut-off
value of 13 KDa) and submerged to 2L de-ionized water (2x) for 4 hours.

2.4.3. Rhenium Coordination

2.4.3.1. Synthesis of (Et4N)2[Re(CO)3Br3]
A suspension of Et4NBr (452 mg, 2.15 mmol) and Re(CO)5Br (400 mg, 988 pmol) in dry
diglyme was heated to 70°C under argon to achieve a clear colourless solution. The
reaction mixture was refluxed at 120°C for 4 hours, and heated at 80°C overnight. The
reaction mixture was cooled to 50°C and the resulting precipitate was filtered, washed
with cold diglyme ( 3 x 5 mL), diethyl ether ( 3 x 5 mL) and cold ethanol ( 2 x 3 mL) to
remove excess Et4N. The solid was dried in vacuo (334 mg, 89% yield) and used without
further purification.
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2.4.3.2. Rhenium coordination
The peptide on solid support was reacted with (NEt4)2[Re(CO)3Br3] (5 equiv.) in
methanol via microwave irradiation (50°C) for 30 minutes. Resins were washed with
DMF (3x) and methanol (3x). The resulting resin was treated with cleavage cocktail and
purified using HPLC as outlined in section 2.4.1.

2.4.4. ELISA binding assay using ModFluoSpheres
A 12-well plate coated with 0.1 mg/mL Rhamm was incubated at 4°C overnight and
washed three times with 0.1% TBST. BSA blocking solution was added and incubated for
4 hours at room temperature. 50pL HA (1 mg/mL) or ModFluoSpheres (1 mg/mL) or
both in 0.1% TBST were added to the plates at 4°C and incubated for 2 hours. After
incubation, plates received a final wash of 0.1% TBST (3x). Negative control plates were
not treated with Rhamm and used to correct for background signals, while positive
control plates (with Rhamm) receive only ModSpheres. Each treatment and controls
were done in triplicate. 100 pL of 0.1% TBST were added to each plate and fluorescence
was recorded for each well.

2.4.5. Cell Uptake Study
MDA-MB-231 cells cultured in FBS were plated in a 12-well tissue culture plate
(confluency of 20000 cells per well) one day after seeding. For blocking experiment,
antibodies (anti-Rhamm mAb) in serum free media were added and incubated at 37°C
for 10 minutes. Peptides (20 pM) were added and incubated at 37°C for 10 minutes.
Cells were washed with serum free media and mounted using fixing solution consisting
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of 0.1M sodium

phosphate (pH 7.4) and 2% paraformaldehyde. Cells were

photographed using Olympus FluoView FV1000 coupled 1X81 Motorized Inverted
System Microscope. Tiff images were analyzed using ImageJ (vl.42q) application. Each
image was converted to an 8-bit format with threshold values of 7 and 259. Region of
interest (ROI) were selected and mean cellular fluorescence was deduced (148 ROIs for
each treatment groups, n = 2).
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3. Ligand-Based Design: Tubulin-Derived Peptides
targeting Rhamm

3.1. Introduction

3.1.1. Microtubules and Rhamm as Tubulin-Binding Proteins
Microtubules are structures which maintain cell morphology and mediate diverse
cellular functions such as mitosis, metabolism, locomotion, trafficking of organelles and
macromolecules.93 Most of these functions involve complex interactions between
microtubules and a large number of microtubule-associated proteins (MAPs). These
interactions regulate polymerization and depolymerization cycles, and the distribution
of microtubules in the cell.94 Microtubules consist of mainly of a(3-tubulin dimers,
whose carboxy terminal region contain a highly conserved helical region and a hyper
variable carboxy terminal tail (CTT) sequence composed of highly acidic (negatively
charged) residues.95'96 Also, y-tubulin, a minor component of microtubules, plays a role
in the nucleation of microtubule assembly.
Tubulin exists in different isotopic forms which have been found to be tissue specific
due to their differential expression and relative stabilities. Furthermore, the majority of
differences between tubulin isotypes are localize within the last 15 residues of the
sequences. There are at least seven different isoforms of a-tubulin, P-tubulin has eight
isoforms, and y-tubulin has seven known isoforms.97 Although the structure of a tubulin
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dimer has been obtained by electron crystallography, the three-dimensional structure of
CTTs has never been determined due to their high structural heterogeneity.98,99 These
CTTs are found exclusively in the tubulin family and are important functionally because
they support the binding of proteins that associate with microtubules.100,101102
In mammalian systems, the carboxy terminus of tubulin undergoes proteolysis with
subtilisin (a serine endopeptidase) to modulate microtubule assembly. Subtilisin
predominantly cleaves the carboxy-terminal residues of each tubulin subunit,
generating the modified tubulin (termed S-tubulin) and releasing short peptides (termed
S-peptides) containing the CTT sequence. These S-peptides have been shown to bind to
MAPs with high affinity; however, covalent cross-linking experiments have shown that
MAPs still bind even with only the last 12 residues (CTT) of a- and (3-tubulin.103 MAPs are
positively charged and they bind primarily to the negatively charged CTTs of both a- and
P-tubulin; thus the binding to microtubules could be dominated by ionic interactions.
Furthermore, P-tubulin derived peptides encompassing the last 12 carboxy-terminal
residues showed MAP-stimulated microtubule assembly in vitro, while peptides derived
directly adjacent to CTT sequences are inactive.104
Microtubule-associated motor proteins are a special type of MAP that couples
adenosine triphosphate hydrolysis to the generation of force and movement to move
cargo along microtubules. Kinesins, a type of microtubule-associated motor protein, are
important in the structural organization of the microtubule system in the cell, especially
during cell division.105 Cross-linking experiments indicate direct binding of CTTs to
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kinesin's motor domain. Specifically, peptides corresponding to the carboxy terminal 12
amino acid residues of pig P-tubulin competitively interfere with the binding of
microtubules to kinesin motors.106

Rhamm is one of a number of proteins that is exported to the cell surface by
unconventional mechanisms due to its lack of signal peptide for export through the
golgi/ER.107 These unconventionally exported proteins are predicted to be both cellsurface proteins and cytoplasmic proteins, and typically have extracellular functions that
are different from their intracellular duties. Aside from being an HA-surface receptor,
Rhamm is also reported to localize exclusively in the cytoplasm in a series of human
breast cancer and various rodent tumour cell lines. 108 This protein localizes at the
perinuclear microtubule network during interphase and may play an important role in
the organization of the cytoskeletal network.109,110 This localization to microtubules is
said to be mediated by the carboxy terminus of Rhamm.111 Protein truncation studies
indicate that the carboxy terminal region alone was sufficient to centralize Rhamm to
mitotic spindle microtubules.112 Also, a pull-down assay showed that Rhamm binds to el
and P-tubulin subunits, and this interaction was strongly reduced in the presence of a
synthetic peptide mimicking the carboxy terminal region of Rhamm.

3.1.2. Rational Design of Tubulin-derived Peptides
Database searches and pairwise comparisons (Figure 13) between Rhamm and
microtubule binding domain of MAPs and kinesins revealed moderate sequence
homology (17%-24% as calculated using ClustalX2113) to the HA binding domain of
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Rhamm; however, MAPs and Rhamm share similar physiochemical properties regarding
the amino acid sequence of their tubulin binding site. In other words, both Rhamm and
MAPs have a stretch of basic residues which are postulated to bind to tubulins.
Furthermore, the secondary structures of the tubulin binding sites of MAPs and
hyaluronan binding site of Rhamm has the same degree of helicity and both could be
classified as a basic-zipper domain.114

A

B

Figure 13: Sequence alignment of the HAbinding domain of Rhamm against: (A) motor
domain of microtubule motor proteins |BJ
tubulin binding domain of microtubule
associated proteins (MIAPsJ. Usiing OustatX2,
each sequence is aligned only to Rhamm- Hie
HA-binding domain of Rhamm is boxed in blade.
Identical, conserved and semi-conserved
residues are denoted by (*), (:), and (.),
respectively.
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Recently, Rhamm has been reported to use a common binding site to associate with HA
in the extracellular surface and microtubules in the cytosol. 115 Since microtubuleassociated motor proteins and MAPs show direct binding to CTTs of tubulin, we
hypothesize that Rhamm could show direct interaction with synthetic peptides
representing the CTTs of different tubulin subtypes. Since HA interacts with Rhamm
mainly through ionic interactions between its negatively charged groups and the
positively charged groups on Rhamm, molecules possessing an analogous distribution of
negative charges can in principle serve as HA mimics. For instance, the Glu and Asp
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residues on tubulin CTTs may mimic the carboxylates on HA. Thus, the binding of
synthetic CTTs to the HA binding domain of Rhamm might utilize the same charged side
chain thought to be important for HA binding.

We investigated the use of known intracellular protein fragments (i.e. CTTs of tubulin)
as extracellular ligands for the cell surface receptor Rhamm. Herein, we describe the
evaluation of different carboxy-terminal tubulin-derived synthetic peptide analogues
and their interactions with Rhamm.
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3.2. Results and Discussion

3.2.1. Initial Studies

Figure 14: General structure of derivatized CTTs used for evaluation. The figure shows the general structure of
unmodified tubulin-derived peptides (a) and peptides conjugated to N-acetyl cysteine (b), FITC (c), and biotin (d).

A six carbon linker was used to increase the distance between the peptide and an
additional peptide modification. Derivatized peptides were prepared with either biotin,
fluorescein or cysteine modified N-terminus (Figure 14). Table 2 describes all peptides
prepared for this study.
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Table 2: Analysis of synthesized tubulin-derived peptides using ESI-MS and RP HPLC.
Tubulin
Calculated
Compd
Sequences
Type
Fragment
M/Z*
3
4a
4b
4c
4d
5a
5b
5c
6
7
8
9
10
11
12a
12b
12c
12d
13a
13b
13c
14a
14b
14c
15
16a
16b
16c
17
18
19

DSADGEDEGEEY
VEGEGEEEGEEY
Ac-C-Ahx-VEGEGEEEGEEY
FITC-Ahx-VEGEGEEEGEEY
Biotin-VEGEGEEEGEEY
SVEAEAEEGEEY
Ac-C-Ahx-SVEAEAE EG EEY
FITC-Ahx-SVEAEAEEGEEY
IDSYEDEDEGEE
DSFEEENEGEEF
LEKDYEEVGVDS
GEFSEAREDMAA
FVHWYVGEGMEE
GEFEEEEGEDEA
EEDFGEEAEEEA
Ac-C-Ahx-EEDFGEEAEEEA
FITC-Ahx-EEDFGEEAEEEA
Biotin-EEDFGEEAEEEA
GEFEEEAEEEVA
Ac-C-Ahx-GEFEEEAEEEVA
FITC-Ahx-GEFEEEAEEEVA
EAFEDEEEEIDG
Ac-C-Ahx-EAFEDEEEEIDG
FITC-Ahx-EAFEDEEEEIDG
SNMNDLVSEYQQ
FTEAESNMNDLV
Ac-C-Ahx-FTEAESN MNDLV
FITC-Ahx-FTEAESNMNDLV
RPDYISWGTQEQ
VQQLIDEYHAAT
DNPDEMDTSREI

ala (438-449)
ala (439-451)

CTT
CTT

alile (439-450)

CTT

alVa (437-448)
aVIll (438-449)
ala (427-439)
ala (416-426)
ala (404-415)
Pila (433-445)
Pia (433-444)

CTT
CTT
H12
H12
H12
CTT
CTT

PIV (433-444)

CTT

pvi (407-418)

CTT

Pilla (413-424)
Pilla (408-419)

H12
H12

Vi (440-439)
yl (428-439)
yl (416-427)

CTT
H12
H12

658.2[M+2Hr
677.7 [M+2H]2*
807.3 [M+2H]2t
928.8 [M+2H]2+
798.3 [M+2H]2*
671.3 [M+2H]2*
800.3 [M+2H]2+
921.8 [M+2H]2+
715.2[M+2H]2*
730.8[M+2H]2+
691.8[M+2H]2+
653.3[M+2H]2+
741.9[M+2H]2+
685.2[M+2H]2*
691.8 [M+2H]2+
821.3 [M+2H]2*
942.8 [M+2H]2+
812.3 [M+2H]2+
684.3 [M+2H)2+
813.3 [M+2H]2+
934.8 [M+2H]2*
706.3 [M+2H]2+
835.3 [M+2H]2+
956.8 [M+2H]2+
714.4 [M+2H]2+
685.2 [M+2H]2*
814.4 [M+2H]2*
935.8 [M+2H]2+
740.4 [M+2H]2+
693.2 [M+2H]2*
711.4 [M+2H]2*

Observed M/Z

Purity
(%jf

657.7 [M+2H]i+
677.6 [M+2H]2+
807.6 [M+2H]2+
927.9 [M+2H]2+
798.1 [M+2H]2+
670.7 [M+2H]2+
800.5 [M+2H]2+
922.1[M+2H]2*
714.7 [M+2H]2+
730.3 [M+2H]2+
691.3 [M+2H]2+
656.3 [M+2H]2+
741.3 [M+2H]2+
684.7 [M+2H]2+
691.9 [M+2H]2t
821.7 [M+2H]2+
943.1 [M+2H]2+
812.6 [M+2H]2+
683.8 [M+2H]2*
813.6 [M+2H]2+
935.1 [M+2H]2*
705.8 [M+2H]2*
835.6 [M+2H]2+
957.1 [M+2H]2+
713.8 [M+2H]2+
684.8[M+2H]2+
814.6 [M+2H]2+
936.1 [M+2H]2+
740.4 [M+2H]2+
693.8 [M+2H]2+
711.3 [M+2H]2+

98
98
98
98
94
97
98
98
99
97
99
98
99
98
99
99
98
90
97
97
96
99
99
98
99
99
98
97
98
95
99

Using enzyme-linked immunosorbent assay (ELISA), the affinity of Rhamm to synthetic
CTTs corresponding to a la - and Pia-tubulin were measured (Figure 15A). Biotinconjugated CTTs (VEGEGEEEGEEY 4d and EEDFGEEAEEEA 12d) were incubated with the
immobilized HA-binding domain of Rhamm (Rhamm-CT), washed to eliminate unbound
peptides, and the presence of bound peptides were detected by the addition of
streptavidin-coupled alkaline phosphatase and a colorimetric phosphatase substrate. As

* The /n/Dcalculated and observed values are based on the prominent observed signals as determined by ESI.
f Percent purity determined by RP H P L C with detection at 220 nm.
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expected, minimal color development corresponding to plates which receive no peptide
or no Rhamm treatment was observed. Results show that both a la - (VEGEGEEEGEEY,
4d) and pia-CTT (EEDFGEEAEEEA, 12d) displays affinity to Rhamm (p = 0.001). Results
also indicate that ala-CTT shows a slightly higher affinity to Rhamm compared to piaCTT (p = 0.01).
To examine the affinity of ala- and pia-CTT to the HA-binding domain of Rhamm, surface
plasmon resonance (SPR) binding assay was utilized. To utilize this technique, peptides
were conjugated to N-acetyl cysteine were synthesized (VEGEGEEEGEEY 4b and
EEDFGEEAEEEA 12b), and their thiol functionality was used for immobilization to the
sensor plate. For this experiment, Rhamm-CT was passed across a peptide-derivatized
surface, and the real time association and dissociation interactions of each peptide to
Rhamm-CT were detected and reported as sensograms (Figure 15B). Sensorgram
indicates that 4b

(VEGEGEEGEEY)

showed

higher binding compared

to

12b

(EEDFGEEAEEEA). This result is good correlation to the results obtained by ELISA.
Equilibrium dissociation constants (KD) were obtained from the resulting sensograms.
Each sensograms was globally fitted to a 1:1 bimolecular kinetic model (Figure 15C) to
obtain the association rate constant (K0 n) and dissociation constant (K0ff)- The
equilibrium dissociation constant (KD) is given the ratio K0ff/K on- Using data from
different

Rhamm

concentrations,

a la -

(VEGEGEEEGEEY,

4b)

and

pia-CTT

(EEDFGEEAEEEA, 12b) had average calculated KD of 24 nM and 32 nM, respectively. Data
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are consistent with our previous reports that the carboxy terminus of Rhamm contains
the tubulin binding domain of Rhamm.114

A

□ Biotin-conjugated a 1 a -C T T (4d) with RHAMM
■ Biotin-conjugated p1a-CTT (12d)with RHAMM

B

Ü No Rhamm
□ No peptide

8-,

□ <xl (4b) (1700 nM)
□ a l (4b) (850 nM)
□ a l (4b) (500 nM)
o pi (12b) (1700 nM)
o pi (12b) (850 nM)
o pi (12b) (500 nM)
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Tim e (s)

Sequence

Compd

Subtype

[Cone.]
(nM)

K on (nM 1 sec *)

VEGEGEEEGEEY

4b

a la

500
850
1700

7052
4412
2795

Koff (sec
d o 4)
1.664
1.168
0.695

500
850
1700

7409
4056
2384

2.522
1.316
0.696

EEDFGEEAEEEA

12b

Pla

)

H

Kd (nM)

Ave. Kd (nM)

23.5
26.4
24.7

24 ± 1.5
If

34.0 11
32.5
29.2

32 ± 2.5

Figure 15: (A) Binding of biotin-conjugated CTTs (4d and 12d) to Rhamm using ELISA (n = 3). (B) Sensograms depicting
the interaction of CTTs (4b and 12b) and Rhamm. An N-terminal acylated Cys spaced by aminohexanoic acid linker
was added to each peptide sequence to permit attachment to the SPR sensor plate. Different concentrations (500,
850, and 1700 nM; traces from top to bottom) of Rhamm was flowed over functionalized SPR sensor plate. Black lines
represent the global fit of the sensograms to a 1:1 interaction kinetic model (C) (Table 3) Kinetic analysis of CTTs (4b
and 12b) interacting with Rhamm. The equilibrium dissociation constant, KD, was calculated from Koff/K on-
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3.2.2. Screening of tubulin-derived peptides
Based on the promising results from the initial a la - and pia-CTT peptides, we then
proceeded to evaluate sixteen tubulin derived peptides. Sequences of synthesized
peptides encompass the CTTs of different tubulin subtypes as well as sequences directly
flanking a la - (i.e. 8, 9 and 10) and pilla-CTT (15,16 and 17). Tubulins were chosen based
on the most common tubulin isoforms arising from a- and p-tubulin gene and the most
acidic region of the protein.116,117 An SPR-based screening method was utilized for rapid
and accurate determination of potential peptide candidates that are able to recognize
the HA-binding domain of Rhamm. Sixteen tubulin-derived peptides were screened, and
the resulting sensograms was used to deduce peptides which show affinity to Rhamm.
Prior to screening, the optimal condition for ligand immobilization and analyte binding
condition was determined. The optimal pH for the immobilization buffer balances the
electrostatic attraction of the protein to the sensor plate while minimizing protein
deactivation. In this study the optimal pH for immobilization was determined to be the
pH that yielded the highest ligand density. Rhamm was coupled to the sensor plate
using sodium bicarbonate buffer of varying pH, at a flow rate of 30 pL/mL and with fixed
concentration of EDAC and sulfo-NHS. The Rhamm ligand density for each pH
immobilization condition was determined from the average SPR response of six
measurements and the maximum ligand immobilization occurred at pH 9.7 (Figure 16A).
Ligand immobilization was slightly lower than pH 10.1 due in part to loss of net charge
on Rhamm at its isoelectric point.
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Buffer Ph

Rhamm Concentration (iig/mL)

Ligand Density (RU)

10.1
9.7
9.1
7.0

30

1 4 4 5 .1 ± 3 1 . 4

30

1 5 4 7 .8 ± 2 9 .0

30

1 4 9 9 .5 ± 3 4 .4

30

1 4 7 5 .4 ± 13.7

9.7

0

2 7 .2 2 ± 3.57*

150D SFE E E N E G E E F
ID SYED ED EG EE
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D SA D G E D E G E E Y
SN M NDLVSEYQQ
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• G EFSEA R ED M A A
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Figure 16: (A) (Table 4) pH dependence off Rhamm-CT immobilization to a SPR sensor plate. Rhamm-CT protein was
immobilized in sodium bicarbonate buffer, pH 7.0-10.1, at a flow rate of 30 pl/m L With Rhamm pi = 10.1, sodium
bicarbonate buffer (pH 9.7) for control was used. Ugaod density was determined from the average SPR response of
six measurements. Proteins were coupled to the sensor plate using EOAC (100 mM) and sulfo-NHS (25 mM). (B) SPR
screening of purified tubulin-derived peptides against Rhamm. Shown are sensograms generated by the interaction of
16 tubulin-derived peptides at a concentration off 10 pM. Screening generated 6 peptides (colored traces) which
show high affinity to Rhamm. Black traces represent low affinity peptides. (C) Binding of fluorescein-labelled peptides
to Rhamm ELISA binding assay (n = 3). Binding studies was performed at 25 pM and 50 pM concentrations of the
peptide. Negative control (no immobilized Rhamm) was subtracted for each measurements.
D Sensograms generated using this ligand density were used a control sensogram for each peptide screening.
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After immobilization of Rhamm on the SPR sensor chip, injection of a series of tubulin
derived peptides was carried out. Association of the peptides with Rhamm proceeded
for 3 minutes and the dissociation in analyte free buffer was carried out for 10 minutes.
Figure 16B shows the experimental sensograms obtained at a concentration of 10 pM.
For each peptide injections, control sensograms (no immobilized Rhamm and buffer
injection) were subtracted from the test sensogram, and the chip surface was
regenerated prior to the next peptide injection in order to remove any remaining bound
peptides. Screening of 17 peptides resulted in six potential peptide ligands for Rhamm
namely:

4a

(VEGEGEEEGEEY),

5a

(SVEAEAEEGEEY),

12a

(EEDFGEEAEEEA),

13a

(GEFEEEAEEEVA), 14a (EAFEDEEEEIDG), and 16a (FTEAESNMNDLV). The affinity of these
six peptides was also verified by ELISA at two different concentrations (Figure 16C).

3.2.3. Characterization of candidate tubulin-derived peptides

3.2.3.1. Affinity of tubulin-derived peptides to Rhamm
Since binding partners were established, the binding of six peptide candidates to
Rhamm was quantified. Peptides were immobilized on the sensor plate and Rhamm was
flowed to the derivatized surface at three different concentrations at a constant flow of
100 pL/mL. Figure 17 depicts the resulting sensograms at three concentration of Rhamm
(500, 750 and 1000 nM). Again, each sensograms has been corrected by subtracting
each curve from a reference sensogram (data achieved from sensograms without
immobilized peptide) due to refractive index differences between running buffer and
sample solution.
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Negati e Control (No Rhamm)
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Time (s)

Figure 17: Seven sets of sensograms showing global fits to
each specific peptide-Rhamm interaction, with negative
control and reference sensogram plot. Each set of
sensogram corresponds to the responses of three Rhamm
concentrations (1000 nM [red], 750 nM [blue] and 500
nM [green]) interacting with immobilized peptide. Lines
depict global 1:1 interaction curve-fitting models for each
of the seven interaction.
Time (s)

• 1000 nM • 750 nM

500 nM
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Experimental sensograms were fitted with curves resulting from a kinetic model for a
1:1 Langmuir binding model. The average values for KD of six peptides obtained from
different Rhamm concentration are given in Table 5 together with the respective
standard errors. As a positive control, the kinetic profile of anti-Rhamm mAb was also
measured and results shows 5.53 nM affinity to Rhamm. Furthermore, the affinity of
VEGEGEEGEEY and EEDFGEEAEEEA in two different independent experiments (shown in
Figure 15B and Table 5) showed identical KD results of 24 and 32 nM. In addition to our
reports on a la - and pla-CTT118 (i.e. VEGEGEEEGEEY and EEDFGEEAEEEA, respectively),
we have discovered another high affinity ligand for Rhamm, containing the sequence
FTEAESNMNDLV (KD = 30 nM).
Table 5: Kinetic profile of selected tubulin derived peptides showing calculated K0N, K0FF and Kp.
Sequence
[Cone.] (nM)
KqN(nM 1sec'1)
KofF (sec1)
K0 (nM)

Ave. K0 (nM)5

( i o 3)
SVEAEAEEGEEY

1000
750
500

1404
1594
1620

0.502
0.517
0.503

358.2
324.6
310.4

331.1 ±24.5

GEFEEEAEEEVA

1000
750
500

855
1189
1485

0.102
0.172
0.187

119.8
144.7
126.0

130 ±12.9

VEGEGEEEGEEY

1000
750
500

5046
9371
9436

0.124
0.224
0.234

24.5
23.8
24.4

24.2 ±0.4

EEDFGEEAEEEA

1000
750
500

5347
5808
7014

0.173
0.196
0.222

32.4
33.8
31.7

32.6 ±1.1

EAFEDEEEEIDG

1000
750
500

1090
1101
1594

0.219
0.237
0.346

201.4
215.4
217.0

211.3 ±8.6

FTEAESNMNDLV

1000
750
500

3202
4033
4189

0.10
0.11
0.12

31.9
29.0
29.6

30.2 ±1.5

Rhamm mAb

1000
750
500

37484
42913
45172

0.22
0.23
0.23

5.96
5.45
S.18

5.53 ±0.4

Errors are standard deviation of the three measurement
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As shown in Figure 16C, ELISA results show peptides 4c (VEGEGEEEGEEY), 12c
(EEDFGEEAEEEA), and 16c (FTEAESNMNDLV) showed the highest relative binding affinity
in all concentrations, thus verifying SPR results. It is possible that the fluorophore
modification has an effect on the ligand-Rhamm interaction or on non-specific binding,
thus SPR and ELISA results might not exactly match.

3.2.3.2. Specificity of tubulin-derived peptides to the HA binding domain of
Rhamm
A competitive ELISA was done to determine the selectivity of the peptides to the HA
binding domain of Rhamm. In this assay, fluorescein-labelled peptides were used and
the effectiveness of unlabelled HA to block the binding of peptides to Rhamm was
evaluated. Fluorescein-labelled peptides (4c, 5c, 12c, 13c, 14c and 16c) were added to
ELISA plates containing immobilized Rhamm, followed by the addition of varying
concentration of HA, which is the natural ligand of Rhamm. Thus, a decrease in observed
fluorescence is seen as HA displaces the fluorescein-labelled peptides if they compete
for the same binding site. Figure 18A shows competitive displacement of peptide
binding to Rhamm by HA, and a concentration dependent decrease in fluorescence is
observed for all six ligands as the HA competitor concentration increases.
An alternative competition experiment was devised to further assess the peptide ligands
since the presence of the label can influence the physical properties of the compound
and the resulting binding potential. Using ELISA, unlabelled peptides (4a, 5a, 12a, 13a,
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14a and 16a) were used to compete with dye-labelled HA. This assay eliminates
confounding results arising from the interaction between the dye label and protein or a
change in affinity caused by the addition of a bulky dye to the peptide ligand. As shown
in Figure 18B, displacement of labelled-HA by non-fluorescent peptides derived from
tubulin is readily observed by decrease of the fluorescence signal. Ligands 16a or 16b
(FTEAESNMNDLV) and 12a or 12c (EEDFGEEAEEEA) appear especially able to compete
for the binding with HA consistently, thus reinforcing our notion that further
modification at the amino terminus of the peptide has little effect on the binding to
Rhamm. However, fluorescein-labelled ala-CTT (4c), which contains the sequence
VEGEGEEEGEEY, seemed better at competing with HA compared to unmodified peptide
(4a).
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10 00 -

C D 4 4 + FIT C -P e p tid e s
C D 4 4 + F IT C -P e p tid e s + HA

[ H Rhamm + F IT C -P e p tid e s
ED Rhamm + F IT C -P e p tid e s + HA
=>

800-

GEFEEEAEEEVA
(13c)

Figure 18: (A) Shows competitive displacement of six seilected fluorescein-labelled peptides by HA, (B) Competitive
displacement of dye-labelled HA by non-JabelMed tubulin-derived peptides using solid phase binding assay, and (C)
shows ELISA binding assay of FITC-conjjugated peptides and purified CD44. Negative control (no immobilized Rhamm
or CD44) was subtracted for each measurement. For figures B and C, 10 pg/mL concentration of the peptides and HA
was used in all cases.
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Results indicate that these peptides could target the HA binding domain of Rhamm.
However to show these HA mimics is specifically targeting Rhamm, it is necessary to test
the affinity of the peptides to other hyaladerins such as CD44 (Figure 18C). To this end, a
solid phase peptide binding assay (ELISA) was performed with a CD44 functionalized
surface. As described above, each FITC-conjugated peptide was incubated to each
hyaladerin (Rhamm or CD44) and the resulting fluorescence measurement was recorded
following extensive washing protocols. As expected, fluorescence measurement arising
from Rhamm and FITC-peptides showed the highest signals, and a remarkable drop in
fluorescence was observed following the addition of HA. Conversely, CD44 and FITCpeptide interaction, as indicated by fluorescence, is significantly lower and fails to show
the expected decrease in fluorescence measurement following the addition of HA. Thus,
the binding of the peptides is caused by a specific interaction with Rhamm, while they
show limited interaction with CD44.

3.2.3.2.I. Serum Stability Studies
To test their potential as targeting entities for therapeutics, the stability of the peptides
(4a, 5a, 12a, 13a, 14a and 16a) in biological environments needs to be investigated. In
vitro serum stability of each peptide was evaluated over a period of 11 hours, and the
quantification of remaining intact peptide was deduced using RP-HPLC. In this assay,
the peptides are subjected to fetal bovine serum at 37°C, and aliquots were taken at 30
minute intervals. At each time point, the reaction was stopped by precipitating serum
protein with trifluoroacetic acid (TFA), and centrifuged to obtain the peptides for further
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analysis. Unmodified tubulin derived peptides showed serum stability with a reasonable
half-life of approximately 2-4 hours (Figure 19).

Figure 19: Serum stability study of six tubulin-derived peptides under physiological amdKtions in fetal bovine serum.
The percentage of intact peptides at 30 minute increments for 11 tours is plotted as a function off time- Data were
fitted to a first order exponential decay curve.

3.2.3.2.2. Tubulin-derived peptides as imaging probes for breast cancer
To determine the specificity of tubulin derived peptides to Rhamm expressing cells and
its potential as targeting entity, a cellular fluorescence assay was performed using MDAMB-231 (a breast cancer cell line) cells treated with anti-Rhamm antibody. MDA-MB-231
breast tumour cell line shows high expression of Rhamm receptors,114 thus this cell line
was an ideal choice for evaluation of the specificities of tubulin CTTs. MDA-MB-231 cells
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were incubated with FITC-conjugated tubulin CTT (4c and 12c) and cellular uptake of the
probe was measured. Probe uptake in cells treated with non-specific antibody (i.e. IgG
antibody) showed high uptake of probe (Figure 20A and Figure 20E); however, cells
blocked with anti-Rhamm mAb (Figure 20B and Figure 20F) and anti-Rhamm pAb (Figure
20C and Figure 20G) showed 25% to 45% reduction in cellular fluorescence compared to
the control assay. This further confirms the specificity of tubulin CTT (4c and 12c) to
Rhamm.
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Figure 20: Visualization and
quantification of uptake of
FITC-conjugated ala-and 01atubulin CTT in breast tumour
cells (MDA-MB-231) using
fluorescence imaging. Nuclei
are shown in blue (DAPI) while
fluoresceinconjugated
peptides are shown in green.
Cells (A), (B) and (C) were
incubated
with
FITCconjugated ala-CTT, while
cells (E), (F) and (G) were
incubated
with
FITCconjugated 01a-CTT. Prior to
the
addition
of
FITCconjugated peptides, cells
were incubated with antibody
blocked
with
different
antibodies specific for the HA
binding region of Rhamm. Cells
blocked with anti-mouse IgG
(A) and (E) serves as positive
control since the antibody
shows no binding affinity to
Rhamm. In (B) and (F), cells
were treated with anti-Rhamm
mAb. Anti-Rhamm (Pep B) pAb
were added to (C) and (H).
Quantification
of
cellular
uptake
of
FITC-labelled
peptides representing a la - (D)
and 01a-CTT (E) in MDA-MB231 breast cancer cell line. ROI
corresponding to cell bodies
(121 ROI, n = 3) were selected.
Mean fluorescence of each ROI
was then calculated using 8-bit
acquired data. Data were
analyzed
using
one-way
ANOVA.

3.2.3.2.3. Common Rhamm binding domain
The described results shown in this report suggest the presence of a common site for
the HA binding domain of Rhamm at the variable carboxy terminal moieties of tubulin. A
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recurring hexapeptide motif was noted in most peptide candidates, and peptides
sharing this acidic carboxy-terminal segment interacted with Rhamm. The motif, EEXEEZ
(where X is A or G, and Z is Y or E), is present in synthetic ala (4a), alile (5a), pia (12b),
and PIV-CTT (13a) (Figure 21). Our present results are in agreement with the previous
reports that the short sequence EEGEE (Paschal et al., 1989) could be involved in tubulin
and MAP binding, a family of proteins which shares sequence homology to Rhamm.119
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Figure 21: Sequence alignment of the four candidate tubulin CTTs as hyaluronan mimics. Identical sequences are
shown in grey while semi-conserved sequences are boxed. Hexapeptide motif, EEXEEZ (where X is A or G, and Z is Y or
E), could be the Rhamm binding region. CTTs were aligned with ClustalX2.

Despite the role of acidic functional groups in HA and Rhamm interaction, results also
suggest that the random occurrence or an increase of these acidic residues within the
CTT region does not appear to be directly influencing the Rhamm-tubulin interaction. It
is surprising that peptides containing DEXEEZ (as seen in peptides 2 and 6) and EEXEDZ
(e.g. peptide 11) motifs failed the initial screening, suggesting that Asp residues within
the first and fifth sequence cannot substitute a similar acidic Glu residues within this
motif. This might suggest that the CTT interaction with Rhamm is mediated by both
electrostatic forces and conformational effects.
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3.3. Conclusion
Using bioinformatics and prior literature, a connection between Rhamm and tubulin
associated proteins was established. Due to moderate homology between the tubulin
binding domain of MAPs and HA-binding domain of Rhamm, further investigation was
performed to determine which peptide fragments of tubulin interacts with Rhamm. In
this study, the specific interaction between Rhamm and novel ligands were deduced.
Using SPR screening, synthetic peptides corresponding to the carboxy terminus of
different tubulin subtypes were analyzed and resulted in six "hit" peptides which show
high affinity for Rhamm. Further in vitro assays of "hits" demonstrated binding affinity
within the nanomolar range and the ability of four these peptides to be displaced by the
endogenous HA demonstrated specificity to the hyaluronan binding domain of Rhamm.
Also, the greater affinity of these peptides to Rhamm compared to another hyaladerin
(i.e. CD44) further confirms specificity.
The potential of these small peptides as targeting entities was explored using stability
studies and a cell based assay. Peptides showed moderate stability (approximately 110250 minutes half-life) in bovine serum, which is long enough to facilitate in vivo imaging.
Interestingly, tumour cells expressing high amount of Rhamm showed high uptake of
fluorescein-conjugated probes, and this uptake is effectively blocked by anti-Rhamm.
This study represents a promising proof of concept for determining novel peptide
candidates using a combination of rational approach and SPR screening.
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3.4. Experimental

3.4.1. Materials
All solvents were used without further purification, and purchased from VWR, Fisher
Scientific, or Sigma Aldrich. Fmoc-Rink amide MBFIA (100-200 mesh) resin, Fmoc amino
acids and HBTU coupling reagent (2-(lf/-benzotriazole l-yl)-l,l,3,3-tetramethyluronium
hexafluorophosphate) for peptide synthesis were obtained from Peptides International.
EDAC (A/-(3-dimethylaminopropyl)-A/@ethylcarbodiimide hydrochloride), sulfo-NFIS (Nhydroxysulfosuccinimide sodium salt) and fluorescein isothiocyanate isomer I (FITC)
were purchased from Sigma Aldrich. NHS-Biotin was obtained from Nova BioChem.

3.4.2. Peptide Synthesis
Elongation of peptidyl resins and purification of peptides were carried out as outlined in
section 2.4.1. Acylation of the amino terminus was done (15 and 10 minutes) using 10%
acetic anhydride in DMF following Fmoc deprotection. FITC coupling was carried out
using FITC fluorescent dye (4 equiv.) and DIPEA (2 equiv.) in DMF for 4 hours.
Full deprotection of cysteine-containing peptides was accomplished using a solution of
94% v/v trifluoroacetic acid (TFA), 1% v/v triisopropylsilane (TIPS), 2.5% v/v H20 and
2.5% v/v 1,2-ethanedithiol (EDT) for 1-1.5 hours. Full deprotection of all other peptides
was done using a solution of 88% v/v TFA, 5% v/v water, 5% m/v phenol, 2% v/v TIPS for
2-4 hours. The filtrate was collected, precipitated using cold tert-butyl methyl ether and
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pelleted via centrifugation at 3000 rpm and -5°C for 10 minutes. Pellets were then
dissolved in distilled-deionized water and lyophilized yielding solid powders.

3.4.3. ELISA binding assay (biotin-conjugated peptides)
A 96-well plate coated with Rhamm (100 pg/mL) was incubated at 4°C for 1 hour. Plates
were washed three times with 200 pL 0.1% TBST. BSA with 0.1% TBST was added and
plates were incubated at 4°C for 4 hours. Biotin-conjugated peptides (50 pL of 50 pM or
100 pM) or HA (50 pL of 20 pg/mL) were added to the wells. Control plates received 50
pL 0.1% TBST. Plates were washed three times with TBST. AP-conjugated streptavidin
goat anti-mouse IgG (100 pL of 1 mg/mL) were added at room temperature followed by
1 hour incubation. Wells were washed three times with TBST. 100 pL of p-nitrophenyl
phosphate (PNPP) (1 tablet in 20 mL APase buffer) was added at room temperature and
absorbance at 405 nm was recorded for each well.

3.4.4. Competitive ELISA experiment using a fluorescein-conjugated peptides
ELISA was carried out to test the ability of FITC-labeled tubulin-derived peptides
compete with HA for binding site with RHAMM.

Recombinant Rhamm (100 pL, 10

pg/mL in 0.05M PBS, pH = 9) was immobilized on 96-well ELISA plates (final
concentration of 1 pg/well) and incubated overnight at 4°C. resulting in final amount of
protein 1 ug/well. Plates were washed three times with (0.05%) PBS-Tween-20 buffer
(200 pL/well), washed with blocking buffer (5% 200 pL/well, PBS-Tween-20)/well), and
incubated for 1 hour at room temperature. Following three washes as described above,
FITC-labeled tubulin derived peptides (final concentration of 1 pg/mL) and HA (100
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pL/well, M.W. 220 kDa, 10 pg/mL in PBS, serial dilutions have been made for HA = 1:1,
1:2, 1:4, 1:8, 1:16) were added to plates and incubated overnight at 4°C. Plates were
washed as described above, and absorbance was measured at 485/535 nm.

3.4.5. SPR binding assay of peptides to immobilized Rhamm
ProteON XPR36 system was used for the selection and ranking of different tubulin
derived peptides against Rhamm. For immobilization of Rhamm, the ProteON GLC
sensor chip surfaces were activated by amine coupling using 100 mM EDAC and 24 mM
sulfo-NHS. Rhamm (30 pg/mL in sodium bicarbonate buffer, pH 9.7) was injected at a
flow of 30 pl/min. A buffer sample was injected on a different sensor plate for use as a
reference. Ethanolamine HCI (1M, pH 8.5) was then injected to deactivate any remaining
surface groups. Peptides (10 pM in PBS-T, 2% DMSO) were injected to a Rhamm
functionalized surface at 50 pL/min for 3 minutes followed by a 10 minute dissociation
(i.e. injection of PBS-T buffer) period. The surfaces were regenerated using two
injections of 30 pL of 1M NaCI prior to the injection of the next peptide. In all
experiments, reference subtraction was performed using data obtained from reference
plate (No Rhamm) and Rhamm functionalized plate.

3.4.6. SPR binding assay of Rhamm to immobilized peptides
After peptide screening, GWC SPRimager®ll system was used to determine binding
kinetic constants. Thiol containing peptides (Figure 14b, Table 2) were immobilized on a
maleimide-functionalized

gold-plated

chip.

For

binding

studies,

a

series

of

concentrations of Rhamm (in milliQ water) were injected over the immobilized peptides.
57

After a 15 min dissociation phase, the sensor chip surface was regenerated for the next
peptide sample injection, via treatment with two 1 min pulse injections of regenerating
buffer (2 M NaCI in HBS-EP, pH 7.4) at 100 mL/min. Baseline returned to the initial value
after the regeneration step, confirming the removal of all bound analytes. Data were
analyzed and the corresponding dissociation constants (KD) were obtained via non-linear
regression fitting to a Langmuir binding model.120 In all experiments, reference
subtraction was performed using data obtained from reference plate (no peptide) and
peptide functionalized plate.

3.4.7. Serum Stability Study
The stability of tubulin CTTs in serum was evaluated for up to 11 hours. Each peptides
were mixed with pre-heated (37°C, pH 7.3 ± 0.1) fetal bovine serum (FBS), (final sample
volume of 3 mL and peptide concentration of 15 pM). The initial time is recorded, and at
each 30 minute time point, 40 pL aliquots were taken from the reaction mixture and
passed through C18 reverse-phase (C18 Sep-Pak©) cartridge. Peptides were eluted from
the cartridge using 3 mL ethanol (70% v/v) with 0.1% TFA, lyophilized, and analyzed
using analytical RP-HPLC (Grace Vydac Protein/Peptide RP-C18 column 4.6 x 250 mm, 5
pm). Employed mobile phase of this system were 0.1% TFA in water (eluent A) and 0.1%
TFA in CH3CN (eluent B). Linear gradient of 10-95% of eluent B at a flow rate of 1.5
ml/min over 20 minutes was used for each peptide sample. Percent intact peptides
were detected using Waters 2998 Photodiode array detector set at 220 and 254 nm,
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and identified using ESI-MS. Half-life of peptides were determined using GraphPad Prism
version 5.01.

3.4.8. Cell Uptake Study
Cell uptake studies and quantification of cellular fluorescence were carried out
according to protocols written on 2.4.5. For blocking experiment, antibodies (IgG
antibody, anti-Rhamm (Pep B) pAb and anti-Rhamm mAb) in serum free media were
added and incubated at 37°C for 10 minutes.
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4. Library-Based Approach:

One-bead

One-Compound

Library for Hyaluronan Mimetic Peptides

4.1. Design and Screening of OBOC Library
Hyaluronan is a glycosaminoglycan implicated in development, cellular repair and
disease processes.15 HA binds to cell-surface receptors, such as CD44 and Rhamm, which
results in its uptake and signalling cascade which ultimately lead to cell migration and
invasion.121 As discussed in Chapter 1, the over-expression of Rhamm and its resulting
interaction with HA has been implicated in the pathology of cancers. HA mimicking
peptides may serve as antagonists that could block the Rhamm-HA interaction thus
limiting the transforming potential of Rhamm. Furthermore, these peptides could also
be useful for imaging probe development and drug targeting.
Another method of discovering novel high affinity peptide sequences for Rhamm
involves the use of a combinatorial peptide library. Using split-mix synthesis method, a
library of 8-mer peptides that mimic the binding capability of HA to Rhamm was
developed. The employed library consists of beads charged with random peptides
consisting of D-amino acids, thus offering proteolysis resistance to the resulting peptide
candidate. Thus, the beads generated represent a collection of peptides which arises
from random combination of D-amino acids. In this study, the aforementioned synthetic
peptide library was screened against Rhamm, thus allowing de novo discovery of new
candidates for HA mimetics.
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4.2. Results and Discussion

4.2.1. Screening of OBOC Library
An eight amino acid library was synthesized on 90 pm TentaGel beads and screened
using Rhamm. The library contains random sequences consisting of nineteen D-amino
acids (excluding cysteine). The library was screened en masse (approximately 1/3 of the
library) to identify candidates which bind to Rhamm using an assay which separates
beads based on their affinity for Rhamm (Figure 22).
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Figure 22: Screening of combinatorial peptide library

Beads containing bound Rhamm were identified and sorted. The peptide sequence for
each bead was elucidated by MALDI-TOF mass spectrometry, and re-synthesized for
testing in biological assay. Table 6 summarizes the resulting characterization of
synthesized 15 "hit" peptides. Lower case letters denotes amino acids with Dconfiguration.
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Table 6: Sequences of HA-mimetic peptides.

Compound
20a
21
22a
23a
24a
25
26
27a
28
29
30a
31
32a
33
34a

-------------------------- r?------

Sequences
Ipmvamgh
rpdyranq
evgqpnfp
erfhedpe
fpyfwyew
yenykdqf
yedqmyee
yedkmyee
qddlehwr
kfpsqnne
nprntrrt
ksynrnpe
hplaqqea
vymkrded
fhqygnsa

Calculated
428.2
510.2
452.7
529.8
619.3
553.3
553.2
553.2
549.3
482.2
564.3
504.3
447.2
527.7
461.7

[M
[M
[M
[M
[M
[M
[M
[M
[M
[M
[M
[M
[M
[M
[M

+2H ]2+
+2H]2+
+2H]2+
+2H]2+
+2H ]2+
+2H]2+
+2H]2+
+2H]2+
+2H]2+
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+

Observed
429.1
510.7
453.2
530.4
619.2
553.7
554.1
554.2
550.5
482.7
564.6
504.9
448.3
528.3
462.2

[M
[M
[M
[M
[M
[M
[M
[M
[M
[M
[M
[M
[M
[M
[M

+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2*
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+
+2H ]2+

Purity
99
97
99
97
98
99
95
99
80
98
98
98
99
94
98

4.2.2. Affinity of "Hit" Peptides
Table 7: HA-mimetic peptides containing cysteine in the carboxy-terminus spaced by aminohexanoic acid linker
moiety.

Compound
20b
22b
23b
24b
27b
30b
32b
34b

Sequences
Ipmvamgh-Ahx-C
evgqpnfp-Ahx-C
erfhedpe-Ahx-C
fpyfwyew-Ahc-C
yedkmyee-Ahx-C
nprntrrt-Ahx-C
hplaqqea-Ahx-C
fhqygnsa-Ahx-C

Calculated

Observed

Purity

536.27 [M +2H ]2+
552.78 [M +2H ]2+
637.79 [M +2H ]2+
727.33 [M +2H ]2+
661.28 [M +2H ]2+
615.84 [M +2H ]2+
555. 29 [M +2H ]2+
569.76[M +2H ]2+

536.43[M +2H ]2+
552.66 [M +2H ]2+
637.98 [M +2H ]2+
725.87 [M +2H ]2+
661.48 [M +2H ]2+
614.61 [M +2H ]2+
555.46 [M +2H ]2+
568.62 [M +2H ]2+

98
97
98
95
97
96
98
98

To validate the ability of these 8-mer peptides to behave as HA mimics, eight peptides
(Table 7) were synthesized containing cysteine residue in the carboxy terminus spaced
by aminohexanoic acid linker. Since peptides are conjugated to Tentagel beads via the
C-terminus, the amino terminus of the peptide is exposed and potentially could be
interacting with the protein during screening, thus additional modification (i.e.
attachment of different moieties for further characterization) is placed on the carboxy-*

** Lowercase letters represent D-configuration of amino acids
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terminus. The resulting cysteine-conjugated peptides were immobilized onto a surface
plasmon resonance (SPR) sensor plate and their affinity for Rhamm was determined.

Com pd

K d (n M )

20b

414
158
124
608
101
764
134

22b
23b
24b
27b
30b
32b

Figure 23: Dissociation constants of selected peptides and their corresponding SPR sensogram.

Experimental sensograms were fitted to a 1:1 Langmuir model to calculate dissociation
constants (KD) for each peptide (Figure 23). Compound 27b, containing the sequence
yedkmyee, showed the highest affinity to binding affinity to Rhamm and had a
calculated KDof 101 nM.

4.2.3. Specificity of "HitHPeptides
Using SPPS, compound 27a, which showed the highest binding affinity to Rhamm, was
synthesized and the binding affinity to Rhamm was examined using ELISA (Figure 24). In
this assay, GST-Rhamm was immobilized, and was followed by the addition of analytes
(27a or HA) onto each ELISA plate. To examine the binding affinity, HA-conjugated
fluorescent beads were added to compete with the binding of each analyte to Rhamm.
After repeated washing, mean fluorescence at 505 nm was recorded. Positive control
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group, which produces the highest fluorescence counts upon addition of HA-conjugated
fluorogenic beads, contains only Rhamm; therefore, peptides that compete with HAconjugated fluorescent beads would produce a lower mean fluorescence. Since HA is
the natural ligand of Rhamm, HA-treated plates produce the lowest mean fluorescence,
thus serving as negative control. Compound 27a has been shown to bind directly to
Rhamm and compete with HA. This might suggest that the aforementioned peptide 27a
is capable of acting as a mimic of HA.

Figure 24: Competitive binding assay of 27a using ELISA. In each assay, GST-Rhamm bound to a 96-well plate was
used as the primary protein. HA-conjugated fluorescent beads were used as competitor and fluorogenic substrate to
monitor binding assay. Positive control plates were treated with HA-conjugated fluorescent beads, while negative
control plates were treated with both HA and HA-conjugated fluorescent beads. Background (no immobilized
Rhamm) was subtracted for each treatment group. Data are the mean of four experiments, analyzed using ANOVA (all
data are statistically significant compared to positive and negative control groups, p<0.01), and error bars shown are
the standard error of the mean. P<0.05 was considered significant.

4.3. Conclusion
Elucidation of novel targeting entities for Rhamm using a library-based method yielded
17 potential ligands for Rhamm. Eight peptides were selected from the pool of hit
peptides and their binding affinities to Rhamm was calculated using SPR. Peptides
showed moderate binding affinities ranging from 0.1-0.7 pM. Furthermore, compound
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27 which had calculated KD of 101 nM showed specificity to the HA binding domain of
Rhamm.

4.4.

Experimental

Tentagel beads (90 pm, 0.5 mmol/g), Fmoc-rink amide MBHA, Fmoc D- and L-amino
acids, and HBTU coupling reagents were purchased from Peptides international. All
solvents were purchased from Sigma Aldrich and/or Fisher used without further
purification.

4.4.1. Peptide Synthesis
All peptides were synthesized using standard Fmoc solid-phase synthesis; and then
prepared and analyzed using methods utilized in Section 2.4.1. Full deprotection of
cysteine-containing peptides was accomplished using methods written in 3.4.2.

4.4.2. SPR binding assay
Protocols and calculations were carried out using protocols outlined in section 3.4.5.

4.4.3. Competitive ELISA experiment using fluorescent HA-beads
A 12-well plate coated with 0.1 mg/mL Rhamm was incubated at 4°C overnight and
washed three times with 0.1% TBST. BSA blocking solution was added and incubated for
4 hours at room temperature. Then, 50pL HA (1 mg/mL) or peptides was added (5 nM,
lOnM, or 20 nM) in 0. 1% TBST to the corresponding wells at 4°C and incubated for 2
hours. Negative control wells were not treated with Rhamm. Positive control plates
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(with immobilized Rhamm) were treated only with HA fluorescent beads. 100 pL of 0.1%
TBST was added to each plate and fluorescence was recorded for each well.

66

5. Synthesis and Characterization of Rhenium fa c
Tricarbonyl Complexes containing Bis-( 1Methylbenzimidazol-2-yl) Ligands
5.1.

Introduction

Recently, rhenium (I) complexes containing the/oc-M(CO)3+ moieties were highlighted
for their potential as surrogates for/oc-99mTc(CO)3+ complexes, which are fundamental
in development of radioactive products for diagnostic applications. The M(CO)3+ core (M
= Re/Tc) is chemically inert due to its low-spin d6 M(l) center, and limited facial
coordination sites about the metal due to the other three facially disposed carbonyl
donors.

Figure 25: Examples of Re(CO)3+ chelators.

It has been shown that 99mTc/Re(CO)3+ chelators containing /V-heterocyclic donors
produces complexes that have high in vivo and in vitro stability.122,123 For example,
bis(pyrazolyl)ethylamine 99mTc(CO)3+ complexes (Figure 25a) has been used to monitor
myocardial

perfusion.124 Furthermore,

bis-(quinolin-2-ylmethyl)amine

99mTc(CO)3+

complexes (Figure 25b) has been conjugated to the primary amine of bioactive
molecules such as fMLF (a peptide containing the sequence N-formyl derivatized Met-
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Leu-Phe), a peptide that binds to the formyl peptide receptor which is over-expressed in
leucocytes.125,126

Bibenzimidazoles have received much attention because of its potential to act as an
antiviral agent127, fluorogenic agent128 and are effective chelating agents for transition
metal ions. 129'130'131 For instance, Hoechst 33258 is a widely used fluorescent probe of
chromosomal DNA structure (Figure 26).128 Also, bibenzimidazoles tend to be very
robust and remain stable under thermal and chemical stresses.132 Bibenzimidazoles are
also easily derivatized to attain the desired spectral properties for use as luminescent
compounds.133,134
H

Rhenium 2,2'-biimidazole and 2,2'-bibenzimidazole rhenium tricarbonyl complexes
(Figure 25c) are important precursors for the construction of luminescent molecular and
supramolecular assemblies.135,136 However, to date, no reports were published which
utilizes 2,2'-bibenzimidazole rhenium tricarbonyl complexes for molecular imaging.
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A s p / G lu

Figure 27: (a) Model of 2-His-l-carboxylate facial triad, a common active site motif in non-heme ironfll) enzymes, (b)
An example of 2-his-l-carboxylate facial triad ligand (i.e. 3,3-bispm!dazo!~2-yf|propi0nic acid) coordinated to rhenium
tricarbonyl core.

The histidine imidazole moiety is essential for the coordination of metals in
metalloproteins; therefore complexes containing ligands consisting of imidazole
derivatives are important biomimetic models of enzyme active sites. 137138 The 2-His-lcarboxylate facial triad is a common motif of active sites in many non-heme iron (II)
enzymes (Figure 27a).139 These enzymes catalyze diverse cellular processes such as
metabolism of amino, nucleic and fatty acids. Tripodal N,N,O-ligands, such as 3,3-bis(lmethylimidazol-2-yl)propionic acid (Figure 27b), mimic this binding geometry and also
allows for facial coordination of rhenium tricarbonyl core.
With the aim of further exploring novel Re(l) complexes for molecular imaging, bi- and
tridentate ligands with a functionalized bis-(lmethylbenzimidazol-2-yl) moiety was
synthesized and complexation with rhenium tricarbonyl core was studied using
spectroscopic techniques such as UV/Vis, NMR and mass spectrometry.
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5.2.

Results and Discussion

5.2.1. Synthesis and characterization of rhenium complexes containing
bidentate ligands
For metal complexes to be considered as potential diagnostic radiopharmaceuticals,
complexes must be kinetically inert to demetallation and thermodynamically stable
towards hydrolysis at physiological pH. To this end, multidentate ligands that forms 5and 6-membered chelate rings upon coordination to a metal are most commonly
utilized.
To confirm the possibility of using rhenium coordinated bibenzimidazole compounds for
molecular imaging, compound 35,141 a previously reported chelator, was synthesized by
reacting 1-methylbenzimidazole (2 equiv.) and nBuLi (one equiv.) at -78°C (Scheme 3).

Scheme 3: Synthesis of 36. (a) nBuLi in hexanes (0.5 equiv.), THF, -78°C. (b) Re(CO)sBr, toluene, 80°C.

The resulting ligand 35 was reacted to (Et4N)2[Re(CO)3Br3] to create rhenium complex
36. Spectroscopic data for 36 is identical to previously reported values, and the reported
crystal structure of this complex indicates that the carbonyl ligands assume facial
coordination at the rhenium center, while the bromide and bis-benzimidazole ligands
coordinates defines the other face of the com plex.140'141 The bibenzimidazole ligand is
70

bent around the rhenium center with an angle of 168° and the N-Re-N angle of 74°
suggests distorted octahedral complex, thus it is postulated that the rheniumbibenzimidazole complex 36 is greatly strained making it less stable in biological
systems.140’142’143
To test the stability of the complex, 36 was incubated with a coordinating solvent,
acetonitrile at 40°C, and the resulting reaction mixture was analyzed using RP-HPLC and
mass spectrometry. Results indicate that the Re(CO)3+ core dissociates from the bisbenzimidazole 36 and forms [Re(C0)3(H20)(CH3CN)2]+ complex in acetonitrile as early as
30 minutes (Table 8). This result further supports the postulate that the complex might
be unstable in biological systems.
Table 8: Percentage of intact complex 36 after incubation with acetonitrile at 40°C at 30 minutes increment for 2
hours.

% Remaining™
85
79
70
65

Elapse Time (min)
30
60
90
120

HHH

To create a more stable complex, a methylene group was added between the
benzimidazole moieties to allow for a less strained complex. This increased flexibility
may allow the ligands to adjust to the steric demands of the metal core and hence
contribute to the overall stability of the metal complexes. Thus, in an attempt to
demonstrate the possibility of increasing the flexibility of 35, chelator 37 was proposed
and synthesized using a modified literature method.144 Ligand 37 was synthesized by

t+ Data were obtained as ratio of integration of diode-array chromatograph of peak corresponding to 36
at different time points compared to time 0.
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reacting 1,2-phenyldiamine and diethyl maionate at elevated temperature using
microwave irradiation (48% yield). Next, ligand 37 was reacted with (Et4N)2[Re(CO)3Br3]
in methanol to afford complex 38 and the product was characterized using NMR and
mass spectrometry.
H

H

CO

37

38

Scheme 4: Synthesis of rhenium tricarbonyl bis-(benzimidazol-2-yl)methane bromide complex (compound 38). (a)
diethyl malonate, HCI (6M), reflux for 24 hours; (b) (Et4N)2[Re(CO)3Br3]/ DCM, RT.

Again, the complex was solubilised in acetonitrile at 40°C and the thermal
decomposition of 38 was analyzed using RP-HPLC and mass spectrometry. Since the
bromide ligand is labile in the presence of coordinating solvents, solvent coordinated
complex is observed. LC-MS analysis showed acetonitrile substitution of bromide atoms
in complex 38 (observed [M]+ = 561.79 m/z, calculated [M]+ = 561.09 m/z) (Figure 28),
but showed no evidence of Re(CO)3+ core dissociation even after 2 hours of incubation
in acetonitrile at 40°C. Mass spectrum of complex also contains both 185Re and 187Re
isotopic ratio of 2:3, respectively. Thus, the introduction of a methylene group within
the bis-benzimidazole ligand (i.e. ligand 37) allows for more flexibility and forms a much
more stable 6-membered chelate ring upon coordination to Re(CO)3+ core.
However, the utility of this complex as a viable Re(CO)3+ core chelator could be
hampered by the low yields of the complex since the N-H of the ligand could also
coordinate with the metal complex. Analysis of the reaction mixture using RP-HPLC and
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mass spectrometry indicates the formation of multiple products showing identical mass
and each contains the expected 187Re and 185Re isotopic ratio.

Figure 28: Mass spectrum of complex 38 after incubation in acetonitrile at 40°C.

To prevent linkage isomers, the N-H of the ligand was methylated to create bis-1methylbenzimidazole rhenium tricarbonyl complex (Figure 29). However, methylation of
ligand 37 proved difficult, thus a new synthetic scheme was designed in order to
develop the desired ligand (Scheme 5).

\

/

Figure 29: N-methylated rhenium tricarbonyl bis-(benzimidazol-2ly)methane chelator bromide complex (46).
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This reaction includes the formation of an intermediate 39 using a reaction which
generates the anion of 1-methylbenzimidazole, which is immediately reacted with
diethyl carbonate. The resulting compound 41 is subjected to reduction via WolffKishner reduction using hydrazine under basic condition.

N'

(i) nBuLi, THF,-78°C

'N v Â

N

-

n 2h 4, koh

-

\

/

reflux

39

41

Scheme 5: Synthetic scheme showing the formation of the desired ligand 40.

l-Methylbenzimidazole has been known to undergo lithiation at the 2-position, and the
lithio derivative has been reported to react with diethyl carbonate at low temperature
in THF to create 39 (Scheme 6). 145,146 Interestingly, reports did not indicate the
formation of 40 as a by-product. Using LC-MS, the reaction mixture post work-up was
analyzed, and it showed 5:1 ratio of alcohol 40 to ketone 39 (Figure 30A). Products were
purified using silica gel chromatography and were fully characterized by NMR (Figure
30B) and mass spectrometry.

(i) nBuLi, THF,-78°C

f

N 'M »

^ o Ao'

*■

Scheme 6: Synthesis of 39 and side-product 40.

The 1H NMR spectrum of 39 and 40 both has a sharp singlet at around 64 ppm
assignable to N-CH3, and a well resolved AA'BB' pattern of two sets of multiplets in the
aromatic region integrating to 2:2:2:2. The simplicity and well resolved peaks establishes
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the high symmetry of ligands. However, 40 showed a singlet at 67.08 ppm
corresponding to CH-OH proton, which is absent in 39.

c

Figure 30: (A) HPLC chromatogram of a reaction mixture (post work-up) showing the ratio (5:1) of products formed.
NMR of purified alcohol 39 (B) and purified ketone 38 (C).
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Compound 50 was also detected in the aforementioned reaction. This by-product is
postulated to form when a second equivalent of nBuLi reacts with an intermediate
formed from the reaction of equimolar amount 1-methylbenzimidazole and diethyl
carbonate in the presence of a strong base (Figure 31).

Chemical Shift flppm)

Figure 31: (A) Proposed mechanism of the formation of by-product 50. (B) 1H NMR of compound 50.

76

Due to the low yield of 39 from the aforementioned reaction, compound 39 was also
prepared by oxidation of 40. This was done using two different methods: (1) Swern and
(2) Dess-Martin oxidation (Scheme 7). Using Swern oxidation, 40 was reacted at low
temperature with dimethylchlorosulfonium chloride, which is formed from the initial
reaction of oxalyl chloride and DMSO. The desired ketone 39 was formed upon the
addition triethylamine (84% yield). Dess-Martin oxidation was also used in order to
produce the desired ketone 39. The alcohol 40 was reacted with Dess-Martin
periodinane in THF at room temperature. In this reaction, the slightly insoluble alcohol is
gradually replaced by the soluble ketone product (95% yield).

ci

Scheme 7: Oxidation of 34 to 35
via (1) Swern oxidation ysiiirug p|
oxafyl chloride and DMSO in
DCM at -78°C, and (ii) EtjN at
room temperature; {2J DessMartin oxidation using 1,1,1triacetoxy-l,l-dihydro-l,2benziodoxol-Sflffl-one in IMF at
room temperature.

Compound 41 was obtained by reduction of 39 using hydrazine under basic conditions
(Scheme 5) in reasonable yield (64%). Ligands 39 and 40 were also coordinated with
rhenium tricarbonyl core to study their coordination properties. Equimolar reaction of
ligands (i.e. 39, 40 and 41) and (Et4N)2[Re(CO)3Br3] in methanol yielded solids in modest
yields. The complexes (Figure 32), having showed extremely low solubility to common
solvents, are soluble in hot DMSO and remained in solution upon cooling.
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Figure 32: Structures of rhenium complexes showing bidentate ligands

The 1H-NMR (d6-DMSO) of complex 45, 46 and 47 showed bidentate coordination of
respective ligands (Figure 33). 1H-NMR data showed similar spectrum in the aromatic
region compared to ligands but shifted slightly downfield. These observations clearly
demonstrate that the metal complex in DMSO was highly symmetric as the two
benzimidazole moieties were equivalent.
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□

Figure 3 3 :1H NMR of rhenium complexes containing bidentate bis-{l-methylbenzimidazol-2-yl) ligands.

The appearance of the two doublets (66.64 ppm and 65.48 ppm, J h,h = 12 Hz) for each of
the hydrogen on the methylene bridge of compound 47 (Figure 33C) is indicative of
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rhenium coordination since each hydrogen becomes diastereotopic upon complexation
to Re(CO)3+ core. Furthermore, 1H NMR spectrum of 40 shows a sharp downfield singlet
(67.08 ppm) corresponding to CH-OH (Figure 30B), which shifts upfield (65.32 ppm) in
46 (Figure 33A).

C a lc: 6 04 .0 9 rrVz

004 77

Figure 34: Mass spectrum (ESI-MS) of each complex indicating acetonitrile coordinated species of 45, 46 and 47.
Spectra shows [M]+ of the corresponding complexes.

High resolution mass spectrometry (HRMS) of 45, 46, and 47 suggests that two
benzimidazole nitrogens and one bromide ligand coordinates with the Re(CO)3+ core.
RP-HPLC and mass spectrometry showed bromide substitution occur for each complex
forming solvent coordinated complexes after solubilisation in acetonitrile at 40°C
(Figure 34). Also, results indicate that for each complex, ligand 39, 40 and 41 remained
bound to the Re(CO)3+ core and are unable to be substituted with acetonitrile. Thus the
addition of the methylene bridge between the two benzimidazole rings has resulted in
an improved stability towards ligand exchange.
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5.2.2. Synthesis and characterization of rhenium complexes containing
tridentate ligands
As a general rule, the chelate effect predicts that stability of complexes increases with
increasing number of chelate rings around a metal core.147,148,149 Multidentate ligands
tend to form a more stable complexes since these ligands tend to undergo slower ligand
exchange processes. Typically, the exchange of a multidentate ligand involves a stepwise
unwrapping of the coordinated ligand, and the opening of chelate rings. Therefore,
tridentate ligands have the potential to form a much more stable complex compared to
bidentate ligands. Ligand 43 has been shown to provide N,N,0 donor set (i.e. arising
from one carboxylate oxygen and two nitrogens on each benzimidazole) and has been
shown to chelate facially to Ru (II) and Fe (II) complexes.150,151 152 Therefore, 43 could
provide the necessary facial donor set for chelating the Re(CO)3+ core.
O Et

Scheme 8: Synthesis of tridentate rhenium chelators 43 and 44. (a) (i) nBuLi in hexanes, THF, -78°C; (ii) ethyl
bromoacetate; (b) (i) NaOH (2M) in THF, RT; (ii) 2M HCI, RT; (c) (i) nBuLi in hexanes, THF, -78°C; (ii) 2(chloromethyl)quinoline.
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Lithiation of 41 at the bridging methylene group with n-butyllithium at -78°C in THF and
subsequent addition of ethyl bromoacetate resulted in the clean formation of 42.
Subsequently, the ester functionality of 42 was hydrolyzed in THF with excess potassium
hydroxide to give 43 after work-up. Products and intermediates were characterized by
mass spectrometry and NMR spectroscopy.

Figure 35: Synthesis of complex 47.

Rhenium coordination of ligand 43 was carried out in dry methanol heated to 40°C using
Re(CO)5Br, and the resulting complex precipitated out of solution after 1 hour (Figure
35). The complex 48 was obtained as white solid and the low solubility of this complex
compared to starting materials allowed for easy separation via filtration. In the *H NMR
of 48, the aromatic hydrogens appear as two doublets and a multiplet, which are
markedly downfield relative to free ligands (approximately A6 = 0.2). Furthermore,
coordination of the carboxylate was confirmed by the upfield shift in hydrogens directly
adjacent to the carbonyl (from 63.48 ppm to 63.15 ppm) after rhenium coordination.
Also the hydrogen at the methylene bridge which appears as triplet at 65.53 ppm in the
free ligand, is shifted to 65.27 ppm in the complex.
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The stability of the complex was also examined in acetonitrile at elevated temperature.
Again, using LC-MS the reaction mixture was analyzed for the formation of acetonitrile
coordinated species. Results indicate the absence of the acetonitrile coordinated
species and only showed the presence of the complex (calculated for

Re [M+H] =

606.1 m/z, observed [M+H]+ = 606.6 m/z) (Figure 36), thus indicating tridentate
chelation of ligand 43.

Figure 36: Mass spectrum (ESI-MS) of complex 47 Indicating tridentate ligand chelation after solubilisation of the
complex in acetonitrile at 40°C.

To test whether the bulky third arm has significant effects in the stability of the rhenium
tricarbonyl complex, 44 was designed, synthesized and rhenium coordinated with
Re(CO)3+ core. To this end, compound 41 was reacted with n-butyllithium at -78°C in
THF, and the resulting anion was reacted with 2-(chloromethyl)quinoline to afford ligand
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44. Ligand 44 was reacted with Re(CO)5CI to give the desired complex 49, which was
characterized by NMR and mass spectrometry.

figure 37:

NMR of compound 44 and ligand 49.

In the 1H NMR of 49 (Figure 37), the aromatic hydrogens are slightly shifted downfield
relative to free ligands. The coordination of the quinoline arm was confirmed by the
minor shift in the aliphatic hydrogens directly adjacent to quinoline nitrogen, from 64.12
ppm in free ligand to 64.07 ppm after rhenium coordination. Furthermore, the hydrogen
at the methylene bridge which appears as triplet at 65.78 ppm in the free ligand, is
shifted to 65.97 ppm in the complex. From the 1H NMR of complex 48 and 49, it is
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observed that the hydrogen at the methylene bridge for both complexes are shifted
downfield compared to free ligand, while the —CH2— group which connects the third
chelating arm and appear as doublet are shifted upfield compared to free ligand.

HRMS of 49 shows tridentate chelation of ligand 44, suggesting that two benzimidazole
nitrogens and one quinoline nitrogen ligand coordinates with the Re(CO)3+ core. Using
RP-HPLC and mass spectrometry, the complex 49 also showed no ligand exchange in
acetonitrile at elevated temperature. Also, the acetonitrile coordinated species was not
observed and only showed the presence of the complex (calculated for

187Re:

[M+H]+ =

689.15 m/z, observed [M+H]+ = 689.98 m/z), thus futher supporting the tridentate
chelation of ligand 43 (Figure 38).

Figure 38: Mass spectrum (ESI-MS) of complex 49 suggesting tridentate ligand chelation after solubillsatliom of tfe
complex in acetonitrile at 40°C.
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5.2.3. UV-Vis Absorption Studies of Bis-l-methylbenzimidazole complexes.
The spectra of the complexes containing ligands 39, 40, 41, 43 and 44 were recorded in
DMSO because of their lack of solubility in other solvents (Figure 39). The absorption
spectra of ligands 40, 41, 43 and 44 show intense band at approximately 280-285 nm,
which are attributed to n-n* transitions. With the exception of slight variation in
absorption bands, the absorption maxima for ligands 40, 41, 43 and 44 are unaffected
by coordination to Re(CO)3+. The extensive conjugation is absent for compounds 40, 41,
43 and 44 due to the methylene spacer, thus the absorption maximum for each ligand is
blue-shifted compared to 39. The absorption of 39 show intense band at 344 nm and on
the basis of the similarity of the spectra to those of related ligands, this band maybe
assigned to n-n* transitions. Also, ligand 39 show pronounced red shift upon
coordination.

86

45

46

47

48

49

Figure 39: UV-Vis absorption spectra of rhenium complexes and their corresponding ligands in DMSO. Black dotted
lines represent absorption of ligands while blue solid lines represent absorption of complexes.

5.3.

Conclusion

In conclusion, the tricarbonyl rhenium complexes incorporating bi- and tridentate bis(lmethylbenzimidazol-2 -yl)

ligands

have

been

obtained

and

characterized

spectroscopically. The introduction of a methylene group between the bis-2,2'benzimidazole moiety increase the stability of the resulting rhenium tricarbonyl
complex. HPLC studies of the rhenium tricarbonyl complex containing bis-(2,2'benzimidazol-2-yl) showed no thermal decomposition in acetonitrile. UV/vis studies
indicate increase red shifting of n-conjugated ligands (i.e. 39) upon rhenium

87

coordination.

Introduction

of

a

bulky

quinoline

moiety

to

the

bis-(l-

methylbenzimidazoyl-2 -yl)methane ligand as the third chelating arm showed no
significant effect on the stability of the complex. The facile Re(CO)3+ coordination of
ligands show some promise as the basis of future rhenium and technetium
radiopharmaceuticals.

5.4.

Experimental

All materials were reagent grade unless otherwise specified. Re(CO)5CI (Strem), 1methylbenzimidazole (Sigma), 1,2-phenyldiamine (Sigma), diethyl carbonate (Sigma) and
diethyl malonate (Sigma) were used without further purification. All reactions were
carried out under argon using conventional Schlenk apparatus. Microwave reactions
were done using Biotage Initiator 2.0 microwave system. All solvents were dried and
distilled prior to use. Analytical HPLC was performed using a Grace Vydac
protein/peptide RP-C18 column (4.6 mm x 250 mm, 5 pm) using a gradient system of (1)
H20 + 0.1% of TFA and (2) CH3CN + 0.1% of TFA. Analytical TLC was carried out on EMD
silica gel 60 F254 plates, and column chromatography was performed using Merck silica
gel 60 (230-400 mesh). 1H and 13C NMR data were obtained using a Varian Mercury 400.
UV-Vis absorption studies were done using Beckman DU 530 spectrophotometer and
10mm quartz cuvettes. Mass spectra were obtained using Finnigan MAT 8200 (EI-FIRMS)
and Micromass LCT (ESI-MS). For compounds containing rhenium, both
peaks were observed, and 187Re mass is reported.
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Re and

Re

5.4.1. Synthesis of Ligands
Synthesis of bis-2,2-l-methylbenzimidazole (35)
To a solution 1-methylbenzimidazole (0.5 g, 3.78 mmol) In dry THF (30 ml.) at -78°C was
added nBuLi (2.5 M, 0.76 mL, 1.9 mmol). The reaction mixture was allowed to warm to
room temperature and stirred for 24 hours. Reaction mixture was quenched 1M HCI,
followed by evaporation of volatiles. Solution was made basic with 2M NaOH and the
resulting

precipitate

was

filtered.

Crude

product

was

purified

using

silica

chromatography (eluent CHCI3) to give 0.37 g of 35 (70% yield). *H NMR (400 MHz,
CDCI3, 25°C):

6

4H,

4.33 (s,

H ben2imid),

= 7.88-7.86 (m,
6H,

2 H, H benzimid),

7.50-7.48 (m, 2H,

H benzimid),

7.40-7.36 (m,

N-CH3) ppm. 13C NMR (400 MHz, DMSO-d6, 25°C):

6

= 142.56,

141.5, 136.22, 123.96, 122.87, 120.32, 110.09, 32.45 ppm. ESI-MS: [M+H]+ = 263.28 m/z
(calc: 263.14 m/z).
Synthesis of bis-(benzimidazol-2-yl)methane (37)
1,2-Phenyldiamine (1.07 g, 9.89 mmol) and diethyl malonate (0.79 g, 4.93 mmol) in 6 M
HCI (20 mL) was heated to 80°C via microwave irradiation for 3 hours. At this
temperature, the reaction mixture turned clear yellow. The reaction mixture was then
heated to 100°C for 5 hours. The solution was cooled and the resulting precipitate was
filtered. The crude material was dissolved in hot H20 containing charcoal; subsequently,
the charcoal was filtered while the solution is hot. The solution was cooled to 0°C, the
precipitate was filtered and recrystallized in ethanohwater (8 :2 ) to afford beige crystals
(0.58 g, 48%). *H NMR (400 MHz, DMSO-d6, 25°C):
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6

= 7.50-748 (m, 4H,

H ben2imid),

7.14-

7 .1 2

(m,

2 4 9 .1 1

4 H , Hbenzimid), 4 . 4 7

(s,

2H,

Ar-CH 2-Ar) ppm.

E S I-M S : [M + H ]+ = 2 4 9 .1 7

m/z (calc:

m/z).

Synthesis of bis-(l-methylbenzimidazol-2-yl)alcohol (40)
To a solution 1-methylbenzimidazole (0.41 g, 3.1 mmol) in dry THF (20 mL) at -78°C was
added nBuLi (2.5 M, 1.2 mL, 3.1 mmol). The color of the solution became bright red on
the addition of the base. The solution was stirred for 1 hour. Subsequently, diethyl
carbonate (180 pL, 1.5 mmol) was added and the reaction was stirred for 30 minutes.
The reaction mixture was allowed to warm to room temperature and was stirred
overnight. The reaction was quenched with 1M HCI (20 mL) and volatiles were
evaporated. The resulting aqueous solution was extracted with DCM (3 x 50 mL) and
was made basic with 5N aqueous ammonia until a precipitate appeared. The product
was filtered and washed with H20 and hexanes. Recrystallization in ethyl acetate:hexane
afforded white crystals (9:1) (0.25 g, 58%). 1H NMR (400 MHz, DMSO-d6, 25°C):
7.97-7.85 (m, 2 H,

Hbenzimid)/

(s, 1H, CH-OH), 3.97 (s,

7.73-7.71 (m, 2 H,

6 H,

Hbenzimid)/

7.54-7.43 (m, 4H,

Hbenzimid)/

N-CH3) ppm. 13C NMR (400 MHz, DMSO-d6, 25°C):

6

=

7.08
6

=

150.56, 134.65, 134.15, 124.62, 116.45, 111. 73, 109.07, 61.22, 31.16 ppm. ESI-MS:
[M+H]+ = 293.15 m/z (calc: 293.13 m/z). EI-HRMS: 292.1332 m/z (calc: 292.1324 m/z).
Synthesis of bis-(l-methylbenzimidazol-2-yl)ketone (39)
Swern Oxidation: To a solution of oxalyl chloride (0.53 g, 4.1 mmol) in DCM at -78°C,
DMSO (0.32 g, 4.1 mmol) was added and the solution was stirred for 30 minutes. The
resulting solution was added to a slurry of 39 (0.12 g, 0.41 mmol) in DCM (30 mL) at 78°C. The reaction was stirred at room temperature for 4 hours, followed by the
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addition of triethylamine in excess. Then, 1M HCI (20 mL) was added to quench the
reaction. Volatites were evaporated, basified with 5N aqueous ammonia until
precipitate appeared. The product was filtered, washed with H20 (3 x 20 mL) and
hexanes (3 x 20 mL). This product was purified using column chromatography (silica;
eluent ethyl acetate/hexane, 1:1) to give 0.10 g of 39 (84%).
Dess-Martin Oxidation: DMP (0.72 g, 1.70 mmol) was added to a slurry of 39 (0.5 g, 1.71
mmol) in dry THF (30 mL) and the reaction was stirred for 48 hours. Over time the
reaction turned clear yellow. The reaction completion was monitored by TLC (1:1
hexane:ethylacetate with 1% Et3N). Then, H20 (30 mL) was added to quench the
reaction, volatiles were evaporated and extracted with DCM (3 x 20 mL). The organic
layers were pooled, dried with MgS04, and purified using silica column chromatography
(DCM:MeOH, 9.5:0.5) (0.47 g, 95%). *H NMR (400 MHz, d6-DMSO, 25°C):
2H,

Hbenzimid)/

7.78 (m, 2H,

6 H,

N-CH3) ppm. 13C NMR (400 MHz, CDCI3, 25°C):

Hbenzimid)/

7.50 (m, 2H,

Hbenzimid)/

6

7.38 (m, 2H,

6

= 7.82 (m,

Hbenzimid)/

4.08 (s,

= 178.91, 146.82, 142.41, 136.77,

126.23, 123.73, 122.92, 110.21, 32.03 ppm. ESI-MS: [M+H]+ = 291.24 m/z (calc: 291.12
m/z). EI-HRMS: 290.1172 m/z (calc: 290.1168 m/z).
Synthesis of bis-(l-methylbenzimidazol-2-yl)methane (41)
A solution of hydrazine hydrate (15 mL), 38 (0.18 g, 0.62 mmol), and KOH (0.103 g, 1.80
mmol) was heated to 80°C for 3 hours, then the temperature was raised to 120°C and
stirred overnight. The reaction mixture was extracted with DCM (3 x 50 mL). The organic
layer was died with M gS04, filtered and volatiles were evaporated. The crude product
was purified using column chromatography (silica; eluent ethyl acetate/methanol,
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9.5:0.5) which gave a white solid (0.11 g, 64%). *H NMR (400 MHz, d6-DMSO, 25°C):
7.55-7.51 (m, 4H,
6H,

H benzimid),

7.24-7.14 (m, 4H,

H benzimid),

N-CH3) ppm. 13C NMR (400 MHz, CDCI3, 25°C):

6

6

=

4.68 (s, 2H, Ar-CH 2-Ar), 3.83 (s,

= 149.12, 142.24, 136.11, 122.71,

122.14, 119.42, 109.30, 30.44, 28.58 ppm. ESI-MS: [M+H]+ = 277.31 m/z (calc: 277.14
m/z). EI-HRMS: 276.1381 m/z (calc: 276.1375 m/z).
Synthesis of 3,3-bis(l-methylbenzimidazol-2-yl)propanoic acid (43)
Synthesis of 42: To a solution of 40 (0.20 g, 0.72 mmol) in

THF

(30 mL) at -78°C was

added nBuLi (2.5 M, 288 pL, 0.72 mmol). The reaction mixture was stirred for 1 hour at 78°C, followed by dropwise addition of ethyl bromoacetate (0.122 g, 0.72 mmol). The
solution was allowed to warm to room temperature and stirred for 24 hours. The
reaction was quenched with H20 (10 mL), volatiles were evaporated, and extracted with
ethyl acetate (3 x 50 mL). The organic layer was dried with magnesium sulphate, filtered
and evaporated. The product was purified using silica chromatography (eluent ethyl
acetate/methanol 9:1) (0.23 g,

8 8 %).

4H,

H benzimid),

Hbenzimid),

CH 2-CH3, J h , h

7.28-7.25 (m, 4H,
=

XH NMR (400 MHz, CDCI3, 25°C):

6

= 7.77-7.75 (m,

5.46 (t, 1H, CH-CH2, J H,H = 7.68 Hz), 4.13 (q, 2H,

7.03 Hz), 3.76 (s, 6 H, N-CH3), 3.60 (d, 2H, CH-CH2, J H,H = 7.46 Hz), 1.19 (t,

3H, CH 2-CH3, J h,h = 7.25 Hz). 13C NMR (400 MHz, CDCI3, 25°C):

6

= 170.75, 151.14,

142.00, 136.41, 122.83, 122.17, 119.71, 109.23, 61.03, 36.18, 35.91, 30.22, 14.03 ppm.
EI-HRMS: 362.1746 m/z (calc: 362.1743 m/z).
Synthesis of 43: To a solution of 42 (0.15 g, 0.41 mmol) in THF (15 mL) was added KOH
(23 mg, 0.41 mmol) in water (2 mL). The resulting solution was stirred overnight.
Reaction was monitored via TLC (eluent ethyl acetate with 1% Et3N). Subsequently, 1
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equiv. of 1M HCI was added. Solvents were evaporated, and the resulting solid product
was dissolved in anhydrous ethanol. Filtrate was collect and recrystallization from
Et0H/H20 (95:5) gave white crystals (0.12 g,
6

= 7.71-7.67 (m, 4H,

Hz), 3.94 (s,

6 H,

CD 3CN, 25°C):

6

H benZimid),

8 8 %).

7.40-7.31 (m, 4H,

N-CH3), 3.48 (d, 2H, CH-CH2,

*H NMR (400 MHz, d6-DMSO, 25°C):

H benzimid),

J H/H

5.53 (t, 1 H, CH-CH2, J H,H = 7.42

= 7.42 Hz) ppm. 13C NMR (400 MHz,

= 171.59, 148.65, 135.04, 133.75, 125.08, 124.96, 116.12, 111.49,

36.02, 32.73, 30.71 ppm. ESI-MS: [M+H]+ = 335.31 m/z (calc: 335.15 m/z).
Synthesis of 3,3-bis(l-methylbenzimidazol-2-yl)-2-methylquinoline (44)
To a solution of 40 (0.11 g, 0.4 mmol) in THF (30 mL) at -78°C was added nBuLi (2.5 M,
160 pL, 0.4 mmol). The reaction mixture was stirred for 1 hour at -78°C, followed by
dropwise addition of 2-(chloromethyl)quinoline (0.18 g, 1.2 mmol). The solution was
allowed to warm to room temperature and stirred for 24 hours. The reaction was
quenched with H20 (10 mL), volatiles were evaporated, and extracted with ethyl acetate
(3 x 50 mL). The organic layer was dried with MgS04, filtered and evaporated. The
product was purified using silica chromatography (eluent CHCI3) which affords white
solid (0.14 g, 84%). XH NMR (400 MHz, de-DMSO, 25°C):

6

= 8.20-8.18 (m, 1H, ArH), 7.92-

7.91-7.87 (m, 1H, ArH), 7.71-7.68 (m, 1H, ArH), 7.56-7.45 (m, 6 H, Ar), 7.21-7.12 (m, 4H,
ArH), 5.78 (t, 1H, CH-CH2, J H,H = 7.82 Hz), 4.12 (d, 2H, CH-CH2, J H(H = 7.82 Hz), 3.71 (s, 6 H,
N-CH3) ppm. 13C NMR (400 MHz, CD 3OH, 25°C):

6

= 159.07, 152.81, 148.22, 142.19,

137.81, 136.59, 130.58, 128.69, 128.45, 127.93, 127.11, 123.84, 123.22, 122.81, 119.45,
110.37, 41.10, 38.37, 30.43 ppm. ESI-MS: [M+H]+ = 418.34 m/z (calc: 418.20 m/z).
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5.4.2. Synthesis of Complexes
Synthesis of rhenium tricarbonyl bis-(l-methylbenzimidazol-2-yl) bromide (36) and
rhenium tricarbonyl bis-(benzimidazol-2-yl)methane bromide (38)
General procedure: (Et4N)2[Re(CO)3Br3] (1 equiv.) was added to a solution of dry
methanol (20 mL) containing 34 or 37. Methanol was evaporated and the resulting solid
was slurried in CHCI3. Precipitate was filtered and washed with DCM (4 x 20 mL) and
hexanes (4 X 20 mL). Sollids was dried and recrystallized in 10% methanol in CHCI3.
Compound 36: (75% yield) *H NMR (400 MHz, DMSO-d6, 25°C):
Hbenzimid),

7.93-7.91 (m, 2H,

H benzimid),

13C NMR (400 MHz, d6-DMSO, 25°C):

7.69-7.64 (m, 4H,
6

H benzimid)

6

= 8.04-8.02 (m, 2H,

4.47 (s,

6H,

N-CH3) ppm.

= 189.58,183.08, 146.48, 140.39, 136.43, 125.80,

117.60, 112.92, 35.32 ppm. EI-HRMS: 611.9550 m/z (calc: 611.9807 m/z).
Compound 38: (8 8 % yield) XH NMR
Hbenzimid)/ 7 . 6 7 - 7 . 6 6

(m,

JH,H =

(d,

12

5 9 7 .9 6 5 0

Hz),

4 .6 6

(4 0 0

MHz, d6-DMSO,

2 H , Hbenzimid)/ 7 . 4 5 - 7 . 4 0

1H,

Ar-CH 2-Ar, J h,h =

12

(m,

2 5 °C ): 6

=

(d,

(m,

2H,

1H,

Ar-CH 2-Ar,

5 9 7 .9 7 2 4

m/z (calc:

4 H , Hbenzimid)/ 5 . 3 2

Hz) ppm. EI-HRMS:

7 .9 7 -7 .9 5

m/z)

Synthesis of rhenium tricarbonyl bis-(l-methylbenzimidazol-2-yl)ketone bromide (45),
rhenium tricarbonyl bis-(l-methylbenzimidazol-2-yl)alcohol bromide (46) and rhenium
tricarbonyl bis-(l-methylbenzimidazol-2-yl)methane bromide (47)
General procedure: Equimolar (Et4N)2[Re(CO)3Br3] was added to a hot (40°C) solution of
dry methanol (20 mL) containing 38, 39 or 40. A precipitate appeared after 20 minutes
and the reaction mixture was stirred for another 2 hours. The precipitate was filtered
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and washed with hot methanol (4 x 20 mL), H20 (4 X 20 mL) and CHCI3 (4 x 20 ml.). The
resulting solid was dried and recrystallized in DMSO.
Compound 45: (65% yield) *H NMR (400 MHz, DMSO-cf6, 25°C):
Hbenzimid),

7.75-7.69 (m, 4H,

DMSO-ck, 25°C):

6

H benzimid),

4.18 (s,

6 H, N - C H 3)

6

= 8.08-8.03 (m, 4H,

ppm. 13C NMR (400 MHz,

= 199.30, 198.21, 177.62, 154.12, 147.12, 147.01, 137.73, 134.96,

127.53,117.47, 35.64 ppm. EI-HRMS: 639.9664 m/z (calc: 639.9756 m/z)
Compound 46: (60% yield) *H NMR (400 MHz, DMSO-d6, 25°C):
Hbenzimid);

4.04 (s,

7.80-7.77 (m,
6 H,

2 H , Hbenzimid);

7.50-7.44 (m, 4H,

6

Hbenzimid);

N-CH3) ppm. 13C NMR (400 MHz, DMSO-d6, 25°C):

= 8.02-7.99 (m, 2H,
5.32 (s,
6

1 H,

CH-OH),

= 197.38, 196.96,

146.84, 145.89, 137.88, 135.29, 124.40, 121.43, 121.09, 69.82, 29.44 ppm. EI-HRMS:
642.0206 m/z (calc: 641.9912 m/z)
Compound 47: (71% yield) *H NMR (400 MHz, DMSO-cf6, 25°C):
Hbenzimid);

7.91-7.58 (m, 2H,

Hbenzimid);

7.60-7.58 (m, 4H,

Hbenzimid);

6

= 8.06-8.04 (m, 2H,

6.64 (d, 1H, Ar-CH 2-Ar,

J h,h = 12 Hz), 5.48 (d, 1H, Ar-CH 2-Ar, JH,H = 12 Hz), 4.15 (s, 6 H , N-CH3) ppm. 13C NMR (400

MHz, d6-DMSO, 25°C):

6

= 198.34, 198.07, 146.67, 140.40, 134.10, 124.64, 123.37,

119.79, 113.20, 33.23, 29.86 ppm. EI-HRMS: 626.0641 m/z (calc: 625.9963 m/z).
Synthesis of rhenium tricarbonyl 3,3-bis(l-methylbenzimidazol-2-yl)propanoic acid
(48) and rhenium tricarbonyl 3,3-bis(l-methylbenzimidazol-2-yl)-2-methylquinoline
(49)
General procedure: Equimolar Re(CO)5Br and 42 or 43 in dry methanol refluxed for 2
hours. The resulting precipitate was filtered and washed with hot methanol (4 x 20 mL),
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H20 (4 X 20 mL) and CHCI3 (4 x 20 mL). The resulting solid was dried and recrystallized in
DMSO.
Compound 48: (85% yield) XH NMR (400 MHz, DMSO-d6, 25°C):
Hbenzimid)/

7.84-7.82 (m,

= 7.51), 4.12 (s,

6H,

DMSO-d6, 25°C):

6

2 H , Hbenzimid)/

7.57-7.50 (m, 4H,

Hbenzimid);

6

= 7.94-7.92 (m, 2H,

5.27 (t,

1H,

CH-CH 2, J h,H

N-CHa), 3.27 (d, 2H, CH-CH2, J h,h = 7.51) ppm. 13C NMR (400 MHz,
= 198.21, 196.99, 186.77, 144.96, 140.12, 134.90, 124.29, 118.47,

118.47, 110.96, 45.29, 33.56, 30.99 ppm. ESI-MS: [M+H]+ = 605.28 m/z (calc: 605.08
m/z). EI-HRMS: 604.0627 m/z (calc: 604.0756 m/z).
Compound 49: (79% yield) *H NMR (400 MHz, DMSO-d6, 25°C):

6

= 8.35-8.33 (m, 1H,

ArH), 8.20-8.18 (m, 2H, ArH), 8.02-7.96 (m, 2H, ArH), 7.83-7.79 (m, 1H, ArH), 7.68-7.62
(m, 3H, ArH), 7.46-7.35 (m, 5H, ArH), 5.98 (t, 1H, CH-CH2, J H,H = 6.64 Hz), 4.07 (d, 2H, CHCH2, J h,h = 7.03 Hz), 3.74 (s, 6 H, N-CH3) ppm. ESI-MS: [M+H]+ = 689.98 m/z (calc: 689.14
m/z).
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